

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15664 A2

(51) International Patent Classification⁷: **A61K 9/00**

(21) International Application Number: **PCT/GB00/03328**

(22) International Filing Date: **31 August 2000 (31.08.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
9920558.5 31 August 1999 (31.08.1999) **GB**

(71) Applicants (for all designated States except US): **BRADFORD PARTICLE DESIGN PLC** [GB/GB]; Unit 69 Listerhills Science Park, Campus Road, Bradford BD7 1HR (GB). **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Princetown, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **YORK, Peter** [GB/GB]; 47 Parish Ghyll Drive, Ilkley LS29 9PR (GB). **WILKINS, Simon, Anthony** [GB/GB]; 8 Beckbury Street, Farsley, Leeds LS28 5BP (GB). **STOREY,**

Richard, Anthony [GB/GB]; 18 Laurel Way, Chartham, Canterbury, Kent CT4 7TJ (GB). **WALKER, Stephen, Ernest** [GB/GB]; Roundwood Grange, Roundwood Road, Baildon, Shipley, West Yorkshire BD17 7JX (GB). **HARLAND, Ronald, Scott** [US/US]; 1 Harlow Court, Yardley, PA 19067 (US).


(74) Agents: **BREWSTER, Andrea, Ruth et al.**; Greaves Brewster, 24A Woodborough Road, Winscombe, North Somerset BS25 1AD (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: **COFORMULATION METHODS AND THEIR PRODUCTS**



(57) Abstract: A coformulation of an active (preferably pharmaceutically active, for instance a COX-2 enzyme inhibitor) substance and an oligomeric or polymeric excipient, containing at least 10 % of the active, between 80 and 100 % of which is amorphous. The amorphous phase is stable, with respect to the crystalline phase(s), for at least three months after its preparation when stored at between 0 and 10 °C. The invention also provides processes, preferably involving SEDSTM particle formation, for preparing such a coformulation.

WO 01/15664 A2



Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Coformulation Methods and their Products

This invention relates to methods for coformulating an active substance and an oligomeric or polymeric excipient. It also relates to the particulate products of such methods.

In particular, it relates to new applications and products of the particle formation technique known as SEDS™ (Solution Enhanced Dispersion by Supercritical fluids), which is described in WO-95/01221 and (in modified versions) in WO-96/00610, WO-98/36825, WO-99/44733 and WO-99/59710. It has been found that this technique may be used to produce novel coformulation products, especially of pharmaceutically active ingredients with oligomer or polymer excipients, having advantageous physicochemical characteristics.

It is known to coformulate pharmaceuticals with polymers in order to modify their solubility profiles and hence, for example, improve the dissolution of an otherwise poorly soluble drug, or slow the dissolution of a highly soluble drug so as to control its release after administration or to reduce its toxicity.

Known techniques for preparing such drug/polymer coformulations include solvent evaporation and coprecipitation, from a mixture of the drug and polymer in a common solvent system. Such approaches are often limited however by manufacturing difficulties, including environmental constraints, solvent problems such as the need for multiple solvent systems and the consequent risk of phase separation, harvesting difficulties and the high levels of polymer often required. Other major limitations tend to be the poor physical properties and processing characteristics of the particulate products, which can be cohesive and difficult to handle, may contain unacceptable levels of residual solvent or non-uniform drug distributions, may suffer poor chemical and physical stability and are often large particles which need to be further reduced in size before they can be processed into commercial products. It can also be difficult to control the morphology of the drug in the system, ie, the relative proportions of its crystalline and (more soluble, and hence generally preferred) amorphous phases.

There is a tendency too for amorphous phase drugs, even in the presence of polymeric excipients, to be meta-stable with respect to the crystalline phase. Over extended storage periods an amorphous drug can revert to its crystalline form, with

consequent changes in its dissolution profile. The degree of instability may depend on storage temperature (in particular with respect to the glass transition temperature, T_g , of the amorphous solid) and humidity, and on relative drug and excipient concentrations. It can also be affected to some degree by the choice of excipient, and even by the manner in which the drug/polymer mixture was prepared. (See references [1] – [5].)

An active substance such as a drug should have stable characteristics under “normal” storage conditions, typically at room temperature and for shelf lives of at least two years. Thus for pharmaceuticals, standards are being developed which require stability for reasonable periods at 25°C. Previous attempts to coformulate drugs with excipients have generally failed to achieve an amorphous phase active with such a high level of stability; in many cases recrystallisation has been observed within days, if not hours ([1] – [5], *supra*).

Matsumoto and Zografi [6] claim more recently to have stabilised the amorphous phase of the drug indomethacin, using poly vinyl pyrrolidone (PVP) as an excipient. They report storage periods of up to 20 weeks at 30°C without recrystallisation, for coformulations containing up to 95% indomethacin. The properties of the system are explained in terms of hydrogen bonding between the drug and polymer, which disrupts the drug dimers associated with the crystalline phase.

The products of the present invention are coformulations of an active substance, typically a pharmaceutically active substance, with an oligomeric or polymeric material. They contain significant amounts of the active substance in its amorphous form, the stability of which can be much greater than in analogous prior art coformulations. They can be used in particular in the design and manufacture of drug delivery systems, to control drug release and/or enhance bioavailability.

According to a first aspect of the present invention, there is provided a coformulation of an active (preferably a pharmaceutically active) substance and an oligomeric or polymeric material, in which between 80 and 100% of the active substance is present in an amorphous as opposed to crystalline form, wherein the amorphous phase active substance is stable, with respect to its crystalline form(s), for at least three months after its preparation when stored at between 0 and 10°C, conveniently 6°C. It is preferably also stable, for the same period, when stored at 25°C.

By "stable" is meant that, over the specified time period, there is no significant change in the X-ray diffraction (XRD) pattern of the coformulation and, where appropriate (ie, where measurable) in its differential scanning calorimetry (DSC) profile. There is preferably no significant change in the dissolution profile of the coformulated active substance. In other words, there is little or no detectable change in the amount of any crystalline form(s) present after the specified time period, preferably less than 10%, more preferably less than 1%, most preferably less than 0.1% change with respect to the initial amount. Yet more preferably, the coformulation contains no detectable crystalline active substance both pre- and post-storage.

For the purpose of assessing stability, the coformulation may need to be stored in a protective atmosphere if it is particularly sensitive to humidity. Low humidity levels, preferably a moisture-free environment or at least between 0 and 5% relative humidity (RH), may be achieved in conventional ways, for instance by storing in moisture resistant packaging or in a desiccator.

The amorphous phase active substance is preferably stable for at least six, more preferably nine or twelve months after its preparation, and is most preferably stable for at least eighteen, twenty four or thirty six months after its preparation.

It is preferably also stable, for the periods mentioned above, when stored at 25°C and up to 60% RH. Even more preferably, it is stable when stored at 40°C, most preferably at 40°C and up to 75% RH.

A coformulation according to the invention is typically an intimate mixture of the active substance dispersed in a "matrix" of the oligomer or polymer excipient, in which the solubility characteristics of the active substance are modified due to the presence of the excipient. Usually the dissolution rate of the active substance will be enhanced by coformulating it, but in some cases (for instance of use in "controlled release" drug formulations) it may be inhibited.

The products of the present invention, when made by a SEDS™ process, tend not only to be more stable but also generally less cohesive, more free flowing (having discrete particles) and easier to handle and process, than analogous coformulations made according to more conventional methods (in particular prior art coformulations containing amorphous or even semi-crystalline actives, which can have extremely poor

handling properties). The products of the invention can also be made with particle sizes down to between 0.1 and 1 μm , with relatively narrow size distributions.

Another advantage of the products of the present invention is that they can generally be prepared in the absence of additional surfactants, which many prior art coformulations require as stabilisers. They also usually contain significantly reduced levels of residual solvents. Moreover, since they are precipitated rapidly from homogeneous active/excipient solutions, they tend to contain more uniform active distributions, a characteristic which is especially important when formulating low dosage drugs.

The coformulations of the invention are preferably prepared by a SEDS™ process, from one or more "target solutions" containing the active substance and/or the oligomeric or polymeric material. It has been found that SEDS™-coformulated products can contain higher levels of amorphous phase active than is often possible using prior art production methods, and more significantly that the amorphous phase is more stable, with respect to reversion to the crystalline phase, than in conventionally produced coformulations. This may be due to increased intimacy of the active substance/excipient mix, and/or to reduced levels of residual solvent, although we do not wish to be bound by these theories. It may also be the case that the SEDS™ method involves such rapid particle formation that neither the drug nor the excipient molecules are able to group themselves with any degree of order as they precipitate. The slower prior art coformulation processes, such as solvent evaporation and spray drying, may result in the formation of "microdomains", small seed crystals that can act as nucleation sites for subsequent re-crystallisation. If a coformulation contains a significant number of such nucleation "seeds", it will almost inevitably revert to the crystalline form on storage, often within a short period.

That SEDS™ may be used to prepare such coformulations is surprising in view of earlier literature on the process. In WO-95/01221, for example, there are examples of drug/polymer coformulations (salmeterol xinafoate and hydroxypropyl cellulose), but although these apparently demonstrate "disturbance" of crystallinity, it is clear from the appended DSC/XRD data that significant amounts of the crystalline drug are still present. Elsewhere in WO-95/01221 and WO-96/00610, there is emphasis on the ability of SEDS™ to yield crystalline materials, and most of the examples in those documents and

in WO-98/36825, WO-99/44733 and WO-99/59710 show highly crystalline products when SEDS™ is used to process organic materials.

Thus, although SEDS™ is a fast precipitation process, which might otherwise have been expected to produce amorphous solids, in fact it has been shown to force the majority of organic compounds into a crystalline state. The addition of a polymer might be expected, as in Examples 10 and 16 of WO-95/01221, to reduce crystallinity levels, but it would not be predicted to achieve 100% amorphous drug systems, particularly at the relatively high drug loadings now found to be possible (in the past, high levels of polymer (80% or greater) tend to have been needed to give any significant reduction in crystallinity [2]). Moreover, the products of the invention have significantly improved long term stability (with respect to active re-crystallisation), which could not have been predicted from the prior art.

By "a SEDS™ process" is meant a particle formation technique as described in WO-95/01221, WO-96/00610, WO-98/36825, WO-99/44733 and/or WO-99/59710, in which a supercritical or near-critical (preferably supercritical) fluid anti-solvent is used simultaneously both to disperse, and to extract a fluid vehicle from, a solution or suspension of a target substance. Such a technique can provide better, and more consistent, control over the physicochemical properties of the product (particle size and size distribution, particle morphology, etc.) than has proved possible for coformulations in the past.

SEDS™ is also a one-step process; it can be used to precipitate both the active substance and the excipient at the same time, either from the same or from separate "target" solutions or suspensions, the target solution(s)/suspension(s) being co-introduced into a particle formation vessel with the anti-solvent, preferably through a coaxial nozzle with an appropriate number of concentric passages.

Other advantages of the SEDS™ process are described in prior art such as WO-95/01221, for example the ability to process sensitive active substances in a light-free and/or oxygen-free environment.

The anti-solvent used in the SEDS™ process is preferably supercritical carbon dioxide, although others (eg, as mentioned in the earlier SEDS™ literature) may be used instead or in addition.

The oligomeric (which includes dimeric) or polymeric material may be any suitable excipient for the active substance, of whatever molecular weight and whether hydrophilic - such as a polyethylene glycol, hydroxypropyl methyl cellulose (HPMC) or polyvinyl pyrrolidone (PVP) - or hydrophobic - such as an ethyl cellulose (EC). It may
 5 be a biodegradable oligomer or polymer such as a polylactide or glycolide or a polylactide/glycolide. It may be crystalline, semi-crystalline or amorphous. It may be a homo- or co-oligomer/polymer, synthetic or naturally occurring.

Examples, of oligomeric or polymeric materials suitable in particular for coformulation with pharmaceutically active substances, include but are not limited to:

- 10 a) traditional "natural" source materials, their derivatives and their synthetic analogues, such as acacia, tragacanth, alginates (for instance calcium alginate), alginic acid, starch, agar, carrageenan, xanthan gum, chitosan, gelatin, guar gum, pectin, amylase or lecithin.
- 15 b) celluloses and cellulose derivatives, such as alkyl (for instance methyl or ethyl) cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose, sodium carboxy methyl cellulose, microcrystalline cellulose or microfine cellulose.
- c) homo- and co-polymers of hydroxy acids such as lactic and glycolic acids.
- 20 d) acrylates and their derivatives, such as the "Eudragit"TM polymers, methacrylic acids, or methacrylates such as methyl methacrylate.
- e) hydrated silicas, such as bentonite or magnesium aluminium silicate.
- f) vinyl polymers, such as polyvinyl chloride, polyvinyl alcohols, polyvinyl acetates, polyvinyl pyrrolidones, cross-linked polyvinyl pyrrolidones or carboxy vinyl copolymers.
- 25 g) polymeric surfactants, such as polyoxyethylene or polyoxypropylene, or polyalkylene oxides such as polyethylene oxides.
- h) phospholipids, such as DMPC (dimyristoyl phosphatidyl choline), DMPG (dimyristoyl phosphatidyl glycerol) or DSPC (distearyl phosphatidyl choline).
- i) carbohydrates, such as lactose, dextrans, cyclodextrins or cyclodextrin
 30 derivatives.
- j) dendrimeric polymers, such as those based on 3,5 hydroxy benzyl alcohol.
- k) poly(ϵ -caprolactones), DL-lactide-co-caprolactones and their derivatives.

1) poly(orthoester)s and poly(orthoester)/poly(ethylene glycol) copolymers, including block copolymers, such as are described in US-5,968,543 and US-5,939,453, also derivatives of such polymers, also such polymers with incorporated esters of short chain α -hydroxy acids or glycolic-co-lactic acid copolymers.

Other suitable oligomers/polymers are listed in the literature on drug delivery systems, for example the report by Brocchini in World Markets Series "Business Briefing", Drug Delivery Supplement [7].

The oligomeric or polymeric material is preferably either a cellulosic material such as EC, HPC or HPMC (including cellulose derivatives), a vinyl polymer such as a polyvinyl pyrrolidone, a polyoxyalkylene (eg, polyoxyethylene or polyoxypropylene) polymer or copolymer or a polylactide or glycolide (including lactide/glycolide copolymers).

The active substance may be a single active substance or a mixture of two or more active substances. It may be monomeric or polymeric, organic (including organometallic) or inorganic, hydrophilic or hydrophobic. It may be a small molecule, for instance a synthetic drug like paracetamol, or a larger molecule such as a (poly)peptide, an enzyme, an antigen or other biological material. It preferably comprises a pharmaceutically active substance, although many other active substances, whatever their intended function (for instance, herbicides, pesticides, foodstuffs, nutraceuticals, etc.), may be coformulated with oligomers or polymers in accordance with the invention. In particular the active substance may be a material having low aqueous solubility, for which coformulation with an oligomeric or polymeric excipient can increase the aqueous dissolution rate and hence facilitate delivery.

In particular, it has surprisingly been found that SEDS™ may be used to coformulate an active substance with an oligomer or polymer even when their respective hydrophilicities are significantly different. Such pairings might previously have been thought incompatible for coformulation. Examples include coformulations of relatively polar actives such as paracetamol, theophylline or ascorbic acid with hydrophobic polymers such as ethyl cellulose.

For some active substances, SEDS™ enables the preparation of coformulations containing higher amorphous phase active loadings than has previously been possible.

Thus, a second aspect of the present invention provides a coformulation of (i) an active substance selected from the group consisting of paracetamol, ketoprofen, indomethacin, carbamazepine, theophylline and ascorbic acid and (ii) an oligomeric or polymeric material, in which between 80 and 100% of the active substance is present in an amorphous as opposed to crystalline form, and in which the active substance represents at least 10% of the coformulation, provided that if the active substance is indomethacin or theophylline, the oligomeric or polymeric material is not polyvinyl pyrrolidone.

In a coformulation according to the invention, preferably between 80 and 100%, more preferably between 90 and 100% or between 95 and 100%, most preferably 100%, of the active substance is present in an amorphous as opposed to crystalline form. The active substance preferably represents at least 1%, more preferably at least 2% or 5% or 10% or 20% or 25% or 30% or 35% or 40% or 50% or 60% or 70% or 80% or 90% of the system. In other words, products according to the invention can contain high loadings of the active substance, of which all or substantially all is present as a single amorphous phase.

Percentage concentrations are weight for weight unless otherwise stated.

Where the active substance is indomethacin and the excipient is ethyl cellulose (EC), preferably between 95 and 100% of the indomethacin is present in an amorphous form, and the indomethacin represents at least 10%, more preferably at least 20% or 25% or 30% or 35%, of the coformulation.

Where the active substance is indomethacin and the excipient is hydroxypropyl methyl cellulose (HPMC), preferably between 95 and 100% of the indomethacin is present in an amorphous form, and the indomethacin represents at least 10%, more preferably at least 20% or 25% or 30% or 35% or 40%, of the coformulation.

Where the active substance is indomethacin and the excipient is polyvinyl pyrrolidone (PVP), preferably between 95 and 100% of the indomethacin is present in an amorphous form, and the indomethacin represents at least 20%, more preferably at least 25% or 30% or 40% or 50% or 60% or 65% or 70%, of the coformulation.

Where the active substance is carbamazepine and the excipient is EC, preferably between 95 and 100% of the carbamazepine is present in an amorphous form, and the carbamazepine represents at least 10%, more preferably at least 20% or 25% or 30%, of the coformulation.

Where the active substance is carbamazepine and the excipient is HPMC, preferably between 95 and 100% of the carbamazepine is present in an amorphous form, and the carbamazepine represents at least 10%, more preferably at least 20% or 25% or 30%, of the coformulation.


5 Where the active substance is theophylline and the excipient is EC, preferably between 95 and 100% of the theophylline is present in an amorphous form, and the theophylline represents at least 10%, more preferably at least 20% or 25% or 28% or 30%, of the coformulation.

10 Where the active substance is theophylline and the excipient is HPMC, preferably between 95 and 100% of the theophylline is present in an amorphous form, and the theophylline represents at least 1%, more preferably at least 2% or 5% or 8% or 10%, of the coformulation.

15 Where the active substance is ascorbic acid and the excipient is EC, preferably between 95 and 100% of the ascorbic acid is present in an amorphous form, and the ascorbic acid represents at least 1%, more preferably at least 2% or 5% or 8% or 10% or 15%, of the coformulation.

20 Where the active substance is ascorbic acid and the excipient is HPMC, preferably between 95 and 100% of the ascorbic acid is present in an amorphous form, and the ascorbic acid represents at least 10%, more preferably at least 20% or 25% or 30% or 35% or 40%, of the coformulation.


Where the active substance is a compound of formula (I):



((Z)-3-[1-(4-chlorophenyl)-1-(4-methanesulfonyl)methylene]-dihydrofuran-2-one) and the excipient is hydroxypropyl cellulose (HPC), preferably between 95 and 100% of the Compound (I) is present in an amorphous form, and the Compound (I) represents at least 5%, more preferably at least 10% or 15% or 20% or 21%, of the coformulation.

5 Where the active substance is a compound of formula (I) and the excipient is a polyoxyalkylene polymer or copolymer, such as a polyoxypropylene-polyoxyethylene copolymer, preferably between 95 and 100% of the Compound (I) is present in an amorphous form, and the Compound (I) represents at least 5%, more preferably at least 10% or 15% or 20% or 24%, of the coformulation.

10 Where the active substance is a compound of formula (II):



((Z)-3-[1-(4-bromophenyl)-1-(4-methylsulfonylphenyl)methylene]-dihydrofuran-2-one) and the excipient is HPC, preferably between 95 and 100% of the Compound (II) is present in an amorphous form, and the Compound (II) represents at least 5%, more preferably at least 10% or 15% or 20% or 21%, of the coformulation.

15 In certain cases, SEDSTM can allow formation of the amorphous phase of active substances which have (to our knowledge) previously only been prepared in their crystalline phase(s). One example of this is the preparation of paracetamol/excipient coformulations. A third aspect of the present invention therefore provides a

20 coformulation of paracetamol and an oligomeric or polymeric material, in which between 80 and 100% of the paracetamol is present in an amorphous as opposed to crystalline form, and in which the paracetamol represents at least 1% of the coformulation.

In such paracetamol coformulations, preferably between 90 and 100%, more preferably between 95 and 100%, most preferably 100%, of the paracetamol is present in

its amorphous form. The paracetamol preferably represents at least 2%, more preferably at least 5%, most preferably at least 8% or 10% or 20% or 25% or 28% or 30% or 35% or 40% or 50% or 60%, of the coformulation. The oligomeric or polymeric material is preferably hydrophobic; most preferably it is an ethyl cellulose. The amorphous phase paracetamol is preferably stable, with respect to its crystalline form(s), for at least three months, preferably six months, more preferably nine or twelve or eighteen or twenty four or thirty six months, after its preparation, when stored at between 0 and 10°C. It is preferably also stable, for the same period, when stored at 25°C, more preferably also at 40°C.

10 Aspects of the invention can also provide methods for preparing the above described coformulations, using a SEDS™ process, as well as the use of a SEDS™ process to prepare the coformulations. In particular, the invention provides the use of a SEDS™ process to prepare a coformulation of an active substance and an oligomeric or polymeric material, in which between 80 and 100% of the active substance is present in
15 an amorphous as opposed to crystalline form, and in which the amorphous phase active substance is stable, with respect to its crystalline form(s), for at least three months after its preparation when stored at between 0 and 10°C. It also provides the use of a SEDS™ process to prepare a coformulation of an active substance and an oligomeric or polymeric material, in which between 80 and 100% of the active substance is present in an
20 amorphous as opposed to crystalline form and in which the active substance represents at least 10% of the coformulation.

Also provided is a pharmaceutical composition containing a coformulation according to the first, second or third aspect of the invention.

The invention further provides a method for preparing a coformulation of an
25 active (preferably a pharmaceutically active) substance and a hydrophobic oligomeric or polymeric excipient, using a SEDS™ process, in which the active substance and the excipient are chosen so that the difference between their respective total specific solubility parameters, δ_t , is between -5 and +5, preferably between -2 and +2 and more preferably zero or close to zero. The excipient is preferably a cellulose or cellulose derivative such
30 as an ethyl cellulose. The invention provides the products of such a method, and the use of a SEDS™ process in it.

A further aspect of the invention provides a method for preparing a coformulation of an active (preferably pharmaceutically active) substance and an oligomeric or polymeric excipient, using an anti-solvent-induced particle formation process (preferably a SEDS™ process), wherein, under the operating conditions used, the active substance is soluble in the chosen "anti-solvent" but the excipient is not. A preferred "anti-solvent" for this method is supercritical carbon dioxide. The active substance is preferably non-polar, as for instance the drug ketoprofen, and the excipient is preferably hydrophilic, for instance HPMC. Again the invention provides the products of such a method, and the use of a SEDS™ process in it.

A yet further aspect of the invention provides a method for preparing a coformulation of indomethacin and polyvinyl pyrrolidone, using an anti-solvent-induced particle formation process, preferably a SEDS™ process. The invention provides the products of such a method, and the use of a SEDS™ process in it.

In some cases, it appears that SEDS™ can yield active/excipient mixes of sufficient intimacy that the initial "burst" of drug release, which tends to occur in the dissolution profiles of conventional systems, can be inhibited or even prevented. Certain coformulations according to the present invention can therefore be used as slow release drug formulations, providing a more uniform rate of drug release without the need for protective coatings or additional reagents. Examples include in particular coformulations of water soluble active substances such as theophylline with relatively hydrophobic excipients such as ethyl cellulose.

This finding is particularly important since the coformulation of an active substance in its amorphous phase would normally be expected to *increase* its dissolution rate. Previous attempts to inhibit dissolution have instead typically involved placing *physical* constraints on the active substance, such as by trapping its particles in a two-phase polymer matrix.

Thus, a further aspect of the invention provides a coformulation of an active (preferably a pharmaceutically active) substance and an oligomeric or polymeric excipient, comprising an intimate single-phase mixture of the active substance and the excipient in which between 80 and 100% of the active substance is present in an amorphous as opposed to crystalline form, from which the dissolution rate of the active substance in an aqueous medium is no higher for the first 30 minutes, preferably for the

first 60 or 90 or 120 minutes, than it is subsequently. Such a coformulation is again preferably prepared by a SEDS™ process.

Yet another aspect of the present invention provides a coformulation as defined above wherein the active substance is a COX-2 selective inhibitor. As used herein “COX-2 selective inhibitor” means an organic compound or pharmaceutically acceptable salt or solvate thereof which is capable of selectively inhibiting the COX-2 enzyme over the COX-1 enzyme.

The COX-2 selective inhibitor may be a diarylheterocycle. As used herein “diarylheterocycle” means an organic compound of the diarylheterocycle genus (or a pharmaceutically acceptable salt or solvate thereof), comprising two substituted or unsubstituted phenyl rings each directly attached to adjacent atoms in a five or six-membered heterocycle or both of said phenyl rings directly attached to the same carbon atom of a C₁₋₃ alkylidene linker, said C₁₋₃ alkylidene linker further attached to one atom in said five or six-membered heterocycle.


The COX-2 selective inhibitor may be a diarylfuranone. As used herein “diarylfuranone” means an organic compound of the diarylfuranone genus (or a pharmaceutically acceptable salt or solvate thereof), comprising two substituted or unsubstituted phenyl rings each directly attached to adjacent carbon atoms in a furanone moiety or both of said phenyl rings directly attached to the same carbon atom of a C₁₋₃ alkylidene linker, said C₁₋₃ alkylidene linker further attached to one carbon atom in said furanone moiety.

The COX-2 selective inhibitor may alternatively be a diarylpyrazole. As used herein “diarylpyrazole” means an organic compound of the diarylpyrazole genus (or a pharmaceutically acceptable salt or solvate thereof), comprising two substituted or unsubstituted phenyl rings each directly attached to adjacent atoms in a pyrazole moiety or both of said phenyl rings directly attached to the same carbon atom of a C₁₋₃ alkylidene linker, said C₁₋₃ alkylidene linker further attached to one atom in said pyrazole moiety.

The COX-2 selective inhibitor may alternatively be an arylpyridylpyridine. As used herein “arylpyridylpyridine” means an organic compound of the arylpyridylpyridine genus (or a pharmaceutically acceptable salt or solvate thereof), comprising one substituted or unsubstituted phenyl ring and one substituted or unsubstituted pyridyl moiety each directly attached to adjacent atoms in a pyridine ring or both said phenyl ring

and pyridyl moiety directly attached to the same carbon atom of a C₁₋₃ alkylidene linker, said C₁₋₃ alkylidene linker further attached to one atom in said pyridine ring.

The COX-2 selective inhibitor is preferably selected from the group consisting of (Z)-3-[1-(4-bromophenyl)-1-(4-methylsulfonylphenyl)methylene] dihydrofuran-2-one, (Z)-3-[1-(4-chlorophenyl)-1-(4-methylsulfonylphenyl)methylene] dihydrofuran-2-one, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone and the compound of Formula (III):



10

(Z)-3-[1-(4-bromophenyl)-1-(4-methylsulfonylphenyl)methylene] dihydrofuran-2-one and (Z)-3-[1-(4-chlorophenyl)-1-(4-methylsulfonylphenyl)methylene] dihydrofuran-2-one are COX-2 selective inhibitors useful for the treatment of acute and chronic pain.

See U.S. 5,807,873 and related applications incorporated by reference herein.

4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide is a COX-2 selective inhibitor approved for the treatment of osteoarthritis and rheumatoid arthritis and is marketed in the U.S. under the tradename CELEBREX® (celecoxib). See, e.g., U.S. 5,466,823 and U.S. 5,563,165, incorporated by reference herein.

4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone is a COX-2 selective inhibitor approved for the treatment of osteoarthritis, treatment of primary dysmenorrhea and management of acute pain and is marketed in the U.S. under the tradename VIOXX® (rofecoxib). See e.g., U.S. 5,474, 995, incorporated by reference herein.

The compound of Formula (II) is a COX-2 selective inhibitor being developed for the treatment of acute and chronic pain. See WO 99/15503 and related applications incorporated by reference herein.

These and other COX-2 selective inhibitors falling within the biarylheterocycle genus or more particularly biarylfurananone and biarylpyrazole genera appear to have low aqueous solubility, suggesting suboptimal bioavailability. Their coformulation with oligomeric or polymeric excipients, in accordance with the present invention, can be
5 expected to enhance their bioavailability

The present invention will now be described, by way of example only, with reference to the following experiments and the accompanying figures, of which:

Figure 1 is a schematic illustration of apparatus usable to carry out methods, and obtain products, according to the invention;

10 Figures 2-5 are SEM (scanning electron microscope) photographs of some of the starting materials and products of Example I below;

Figures 6 to 8 show dissolution profiles for three of the systems investigated in Example I;

15 Figures 9 to 19 show plots of crystallinity against drug weight fraction for the systems investigated in Example I;

Figures 20 to 24 are DSC (differential scanning calorimetry) traces for, respectively, crystalline indomethacin and a number of coformulations prepared in Example I, including after 24 months' storage;

20 Figures 25 and 26 are plots of $(\delta_s^d - \delta_s^p)$ against X (see Table 10 below) for some of the systems investigated in Example I;

Figures 27 and 28 are SEM photographs of some of the products of Example II;

Figures 29 and 30 are plots of crystallinity against drug weight fraction for the products of Example II; and

25 Figure 31 is a plot of crystallinity against drug weight fraction for the products of Example III.

Examples

30

The following experiments demonstrate the use of a SEDS™ process to coformulate various drugs and polymers in accordance with the present invention. The

physicochemical characteristics of the products, in particular the degree (if any) of drug crystallinity, the stability of the amorphous phase and the relative concentrations of the drug and the polymer (ie, the drug "loading"), were tested and where possible manipulated by altering the operating conditions and solvents present.

5 The drugs were chosen to cover a broad range of polarities, including the highly apolar ketoprofen and, in ascending order of polarity, indomethacin, carbamazepine, paracetamol, theophylline and ascorbic acid. These drugs were coformulated with both hydrophobic (EC) and hydrophilic (HPMC) polymers.

 Ketoprofen was on the whole too soluble in supercritical carbon dioxide (the
10 chosen anti-solvent) to produce meaningful results, even under moderate processing conditions. Surprisingly, however, it could be retained to a degree when coformulated with HPMC.

 In an additional investigation, PVP was coformulated with the poorly water soluble drug indomethacin.

15 Further experiments (Examples II and III) coformulated two cyclo-oxygenase-2 (COX-2) enzyme inhibitors with HPC and, in the case of Example II, a polyoxypropylene-polyoxyethylene block co-polymer, Pluronic™ F87.

 In Example IV, the drug glibenclamide was coformulated with 75/25 DL-lactide-co-caprolactone.

20

Experimental details

 The method used was essentially the SEDS™ process described in WO-
25 95/01221. It is envisaged that modifications of SEDS™, as described in that document, WO-96/00610, WO-98/36825, WO-99/44733 and/or WO-99/59710, could be used to similar effect.

 The apparatus is shown schematically in Figure 1, in which 1 is a particle
formation vessel; 2 is a device (eg, a filter) for retaining the particles formed; 3 is an oven
30 and 4 a back pressure regulator; and 5 is a nozzle for co-introducing, into the vessel 1, a supercritical anti-solvent from source 6 and a target solution from source 7. The items labelled 8 are pumps; 9 is a cooler, 10 a heat exchanger and 11 a pulse dampener. A

recycling system 12 allows solvent recovery at 13 (via needle valve 14), whilst returning carbon dioxide to the cooler 9 for re-use.

The nozzles employed at 5 were two-passage coaxial nozzles of the general form depicted in Figure 3 of WO-95/01221, typical dimensions being as described in that document. Supercritical carbon dioxide was the chosen anti-solvent, introduced into a 50 ml particle formation vessel via the inner nozzle passage. The "target solution", ie, a solution of the drug or polymer, or more typically of both together, was introduced through the outer nozzle passage.

In situ mixing of separate drug and polymer solutions could have been achieved using a nozzle having three or more coaxial passages, allowing the two solutions to meet at the nozzle outlet.

Selection of a suitable solvent depended on the properties of both drug and polymer, but particularly on the latter because of the potential difficulties of processing polymeric solutions and dispersions. Polymeric dispersions can exhibit very high viscosities, even when dilute, whereas in "good" solvents the polymer matrix will relax and loosen, allowing both a greater degree of interaction and a lower viscosity, important respectively for the production of intimate drug/polymer mixtures and for the processing requirements of SEDS™ [8].

The analytical techniques employed in the experiments were as follows:

20

Scanning electron microscopy (SEM)

Particle size and morphology were investigated using an Hitachi™ S-520 scanning electron microscope (Hitachi, Japan). Aluminium stubs containing a small quantity of sample particulate were sputter-coated with a gold layer ~300Å thick and viewed and photographed under varying magnifications.

25

Differential scanning calorimetry (DSC)

This technique was used to measure sample crystallinity, given that the lower the order of the crystal lattice the less energy required for melting the sample. DSC was used to determine thermal profiles, to monitor the latent heat of fusion (ΔH_f), to identify any phase or polymorphic transitions and desolvation phenomena, and to determine melting points and glass transition temperatures.

30

A Perkin-Elmer™ DSC 7 (Perkin-Elmer Ltd, UK) was used. 1-5 mg samples were examined in pierced, crimped aluminium pans, under an atmosphere of nitrogen. The analytical temperature range depended on the drug investigated. Theophylline sublimed just above the melting point, causing difficulties in measuring endotherm peak size. This problem was overcome by adopting a sealed pan method.

Relationships between product crystallinity and weight fraction of drug in the product were also investigated. Crystallinity was derived from the latent heat of fusion (ΔH_f), using the equation:

$$\% \text{ crystallinity} = \frac{\Delta H_f (\text{coformulation})}{\Delta H_f (100\% \text{ crystalline})} \times \frac{100}{\text{Weight fraction of drug}}$$

X-ray diffraction (XRD)

This was also used to give a qualitative assessment of crystallinity. Samples were analysed on a D5000 XRD (Siemens, Germany) between 5 and 30° 2θ.

UV spectrophotometry (Example I)

The weight fraction of drug in samples was measured with an Ultrospec™ 4000 spectrophotometer (Pharmacia Biotech, Cambridge, England), from reconstituted solutions of the samples. The absorbance of the polymers was negligible at the wavelengths used.

Dissolution test (Example I)

Dissolution testing was carried out using a stirred vessel technique and UV analysis. The apparatus consisted of a 1 litre round-bottomed vessel maintained at around 37°C in a water bath, stirred by paddle at 60 rpm. The medium was circulated using a peristaltic pump through a 10 mm flow cell. UV readings were taken every 30 seconds using an Ultrospec™ 4000 spectrophotometer (*supra*) and analysed for up to between 30 and 60 minutes.

Three systems were analysed: paracetamol/HPMC, theophylline/EC and indomethacin/HPMC. The conditions for the individual systems were:-

Paracetamol/HPMC: 247 nm, $37 \pm 0.5^\circ\text{C}$, 500 ml distilled water.

Theophylline/EC: 273 nm, $37 \pm 1.0^\circ\text{C}$, 350 ml distilled water.

5 Indomethacin/HPMC: 235 nm, $37 \pm 0.5^\circ\text{C}$, 400 ml pH 7.00 ± 0.02 0.05M NaH_2PO_4 aqueous buffer.

A different medium was needed for the indomethacin system due to the drug's poor water solubility. The chosen medium provided a compromise between observing drug release within a practical time span and allowing sufficient discrimination to identify
10 true dispersions.

The release profile characteristics were compared with physical mixes to give an indication of polymer/drug interaction and possible complex formation. The physical mixes were prepared from pre-micronised drug ground (for 1 minute in a pestle and mortar) together with the designated polymer. Samples were transferred to hard gelatine
15 capsules (size 4 clear/clear, weighted by 60:40 tin/lead wire coils) for analysis. The capsules gave no significant absorbance in the analysis region.

Aerosizer-Aerodisperser™ particle size analyser (Example II)

Particle size analysis was carried out using a time-of-flight analyser (Aerosizer™
20 with Aerodisperser™, TSI Inc, USA). This instrument is capable of sizing dry powder samples over the range 0.2-700 μm . The powder is dispersed in air and the air/particle suspension is expanded through a nozzle into a partial vacuum. The air/particle stream accelerates through a measuring region, where the particles pass through two consecutive laser beams. Smaller particles experience a greater acceleration than larger ones and
25 hence move more rapidly between the two beams. From measurements of the time taken to travel between the beams and the known density of the material, the Aerosizer™ software calculates the mean size distribution of particles present in the sample. The data obtained complements SEM observations. No sample preparation is required.

30 HELOS Sympatec™ particle size analyser (Examples II and III)

This instrument uses laser diffraction to determine particle size distributions of solid particulate materials. It is capable of measuring across the particle size range 0.1-

8750 μm . A dry powder sample is introduced, via a vibrating conveyor feeder, into a dry dispersing unit. Here the powder and any agglomerates present are fully dispersed in air. The dispersion of single particles is then propelled by compressed air and fed through the measuring zone, where the particle stream interacts with a monochromatic high energy beam from a He-Ne laser. The laser light is diffracted and detected by a multicomponent photodetector. The intensity of the diffracted light is then converted into an electrical signal, which is used to calculate the particle size distribution. Again, the data complements SEM observations. No sample preparation is required.

10 **High performance liquid chromatography (HPLC) (Examples II and III)**

Compound (I) and (II) loadings were determined by HPLC using UV detection. An isocratic method was followed, employing a single mobile phase (0.1% phosphoric acid:acetonitrile (62:38 v/v), degassed for 20 minutes before use).

Quantification was by external standardisation. Two stock solutions of Compound (I) with concentrations of 500 μgml^{-1} were prepared in the mobile phase. Appropriate volumes were alternately taken and diluted with mobile phase to produce a set of standard calibrants in the nominal range 2 to 10 μgml^{-1} . Aliquots of prepared sample solutions, diluted if necessary, were then submitted to HPLC analysis, interspersed with the calibrant solutions. Using the following nominal conditions a chromatogram was generated.

Pump:	Capable of delivering 1.1 mlmin^{-1}
Sample size:	20 μl (ATI Unicam™ autosampler)
Column:	150 x 4.6 mm, ZORBAX™, RX-C8, 5 μm
Column temperature:	30°C
Flow rate:	1.1 mlmin^{-1}
Detector/wavelength:	Jasco™ UV-975 / 220 nm
Peak response:	Area
Cycle time:	Typically 17 minutes

All peak area measurements and calculations were performed using Borwin™ chromatography software Version 1.22.01.

5 Example I


The materials used in this series of experiments were as follows; their polarities and solubility parameters are listed in Table 1 below.

<u>Material</u>	<u>Supplier</u>	<u>Grade</u>
L-ascorbic acid	Sigma Chemical Co, St Louis, Missouri, USA	General laboratory reagent
Carbamazepine	Sigma	Ditto
Indomethacin	Sigma	Ditto
Ketoprofen	Sigma	Ditto
Paracetamol	Sigma	99.0%+
Theophylline	Sigma	Anhyd. 99%+
EC	Colorcon, Dartford, England	7 cps
HPMC	Shinetsu Chemical Company, Tokyo, Japan	3 cps (603)
PVP	Sigma	Av. mol. wt. 10,000
Dichloromethane	BDH (Merck), Poole, England	AnalaR 99.5%+
Chloroform	BDH	AnalaR 99.0-99.4%
Ethanol	BDH	AnalaR 99.7-100%
Ethanol	Rathburn Chemicals Ltd, Walkerburn, Peebleshire, Scotland	HPLC
Methanol	BDH	AnalaR 99.8%+
Sodium dihydrogen orthophosphate	Sigma	99.0%+


(De-ionised water was obtained from a Jencons Waterstill™ 4000X.)

10

<u>Material</u>	<u>Chemical structure</u>
L-ascorbic acid	




Carbamazepine




5

Indomethacin




10


Ketoprofen




Paracetamol
(US acetaminophen)




Theophylline



5 Ethyl cellulose (EC)



Hydroxypropyl methyl
Cellulose (HPMC)



10

Polyvinyl
Pyrrolidone (PVP)




Table 1 Polarity and solubility parameters of drugs and polymers studied*

Material	Polarity	δ_d (MPa ^{1/2})	δ_p (MPa ^{1/2})	δ_h (MPa ^{1/2})	δ_s^* (MPa ^{1/2})	δ_t (MPa ^{1/2})
Ethyl cellulose	0.34	16.7	2.9	11.7	12.4	20.6
Hydroxypropyl methyl cellulose	0.69	13.7	6.5	14.9	16.3	21.3
Ascorbic acid	0.71	21.0	14.0	30.0	33.1	39.2
Carbamazepine	0.23	22.0	7.6	9.6	12.2	25.2
Paracetamol	0.40	21.1	8.5	15.0	17.2	27.3
Indomethacin	0.19	21.9	5.6	9.1	10.7	24.4
Theophylline	0.53	17.4	13.1	12.8	18.3	25.2

5

*Values obtained from published literature

$$^*\delta_s = (\delta_p^2 + \delta_h^2)^{1/2}$$

In Table 1, δ_d , δ_p and δ_h are the partial solubility parameters representing
 10 dispersive, polar and hydrogen bonding effects respectively; δ_t is the total solubility
 parameter, where $\delta_t^2 = \delta_d^2 + \delta_p^2 + \delta_h^2$ [9]; δ_s is the total specific (ie, polar and hydrogen
 bonding) solubility parameter.

The principal operating conditions (temperature, pressure, fluid flow rates and
 nozzle orifice diameter) were manipulated and optimised for each drug/polymer system.

15 Different drug:polymer concentration ratios were also tested.

It was found that temperatures in the range 34-50°C and pressures between 80 and 100 bar were preferable for processing these polymers. Anti-solvent:target solution flow rate ratios (into the particle formation vessel) were between 66:1 and 200:1, ie, an anti-solvent flow rate of 20 ml/min was used with target solution flow rates of between 0.1 and 0.3 ml/min.

Nozzle outlet internal diameters were between 100 and 500 µm, 100 µm being preferred over those greater than 200 µm.

A 1:1 mixture of ethanol and dichloromethane (or 1:1 ethanol/chloroform in the case of PVP) was used as the drug/polymer solvent. This yielded dispersions of suitably low viscosity, enabling processing without significant nozzle blockage. Similarly, ethanol was found to produce low viscosity dispersions for the EC systems. A polymer concentration of 0.5% w/v provided a balance between the ability to pump the solution at a moderate back pressure and an acceptably high material throughput.

To facilitate processing, the polymers used were selected from the lower molecular weight fractions - 3 cps HPMC, 7 cps EC and PVP of average molecular weight 10,000.

Results & discussion

The results of the various experimental runs (in particular yield, morphology and drug loading) are summarised in Tables 2 (ascorbic acid), 3 (carbamazepine), 4 & 5 (indomethacin), 6 & 7 (ketoprofen), 8 (paracetamol) and 9 (theophylline), appended. The tables also indicate the operating conditions (temperature and pressure within the particle formation vessel, fluid flow rates, target solution concentration and nozzle tip (outlet) diameter) for each run.

The products were in the form of finely dispersed particulates; all were non-cohesive, easy-flowing powders with good handling properties. Their morphology was assessed using SEM, which revealed the non-crystalline products typically as fine, agglomerated, roughly spherical particles of the order of 0.05-1 µm diameter. The homogeneity in the appearance of the particles suggested they comprised molecular-level dispersions. Above the amorphous limits detected, mixtures of such web structures with additional, larger drug crystals were observed in many cases.

Figures 2 to 5 are SEM photographs of some of the starting materials and products of the experiments. Specifically, Figure 2 shows the indomethacin raw material (at 2000x magnification); Figure 3 shows the amorphous indomethacin/HPMC product of experimental run RASE 21 (2000x magnification); Figure 4 shows the paracetamol raw material (200x magnification) and Figure 5 shows the amorphous paracetamol/HPMC product of experimental run RASF 34 (1000x magnification).

Dissolution tests

Figures 6 to 8 show dissolution profiles for three of the systems investigated, namely paracetamol:HPMC (Figure 6), theophylline:EC (Figure 7) and indomethacin:HPMC (Figure 8). The labelling corresponds to that used in Tables 2-9 for the various experimental runs; X (%) is the maximum concentration of the amorphous phase of the drug prior to the detection of crystallinity. In all three systems, there were significant differences in drug release rates between the SEDSTTM-coformulated products and purely physical mixes of the relevant drug and polymer, suggesting that the products of the present invention had been formed as intimate molecular level dispersions of a drug in a polymer matrix. For instance, the release of theophylline was significantly inhibited by coformulating it with EC according to the invention, that of paracetamol was also slightly inhibited by coformulation with HPMC, whilst the dissolution rate of indomethacin was increased on coformulation with HPMC (including one sample above the amorphous detected limit).

Degree of crystallinity

Plots of drug crystallinity (determined by DSC) against drug weight fraction are shown in Figures 9 to 19. The systems illustrated are ascorbic acid/EC, ascorbic acid/HPMC, carbamazepine/EC, carbamazepine/HPMC, indomethacin/EC, indomethacin/HPMC, indomethacin/PVP, paracetamol/EC, paracetamol/HPMC, theophylline/EC and theophylline/HPMC respectively.

Although it depended very much on the drug and polymer involved, in general the proportion of amorphous to crystalline drug present in the SEDSTTM products was found to be higher than that achieved using conventional processing techniques such as evaporation and coprecipitation from solvent systems [1]. For instance, maximum

amorphous phase concentrations for indomethacin were $25\pm5\%$ with EC, $35\pm5\%$ with HPMC and $60\pm5\%$ with PVP. Up to 10-15% amorphous ascorbic acid was achieved in coformulation with EC, and up to 35-40% with HPMC (Figures 9 and 10). (Note that drug concentration *ranges* are quoted at the limit of the amorphous/crystalline state boundary, due to the limitations of the method of quantifying crystallinity by DSC and the limited number of data points around the phase change concentration.)

These results are of particular significance for poorly water soluble pharmaceuticals, for which the amorphous form is generally preferred because of its superior dissolution rate.

Physical and chemical stability

The medium to long term storage stability of several of the Example I products was investigated. In all cases the physical properties of the samples were unchanged even after up to 24 months' storage; the samples remained free flowing and easy to handle.

Chemical stability (in terms of amorphous phase contents) was assessed using DSC. Looking firstly at the indomethacin/PVP system, the drug in its crystalline form exhibits a peak in DSC profiles at $150-165^{\circ}\text{C}$, when analysed at a scanning rate of $20^{\circ}\text{C}/\text{min}$. This peak shifts to lower temperature in coformulated indomethacin/PVP systems. Figures 20 and 21 show DSC profiles for, respectively, the crystalline raw material and the indomethacin/PVP system prepared in experimental run RASE 64. The peak at 139°C in Figure 20 indicates the presence of crystalline indomethacin in the sample (which contained 78% w/w indomethacin, with 30% crystallinity).

The indomethacin/PVP samples prepared in experimental runs RASE 70, RASE 69, RASE 62, RASE 66 and RASE 63 (containing 16, 20, 48, 51 and 62% indomethacin respectively), were assessed initially and after both 12 and 24 months' storage in a desiccator at between 2 and 8°C . The DSC results indicated no crystallinity in any of the samples even after 24 months. An example DSC profile for the RASE 63 sample at 24 months is shown in Figure 22; the absence of the 139°C peak indicates an absence of crystalline indomethacin.

Three theophylline/EC systems were also tested, after storage at ambient temperature and without desiccation. The DSC profiles obtained after 24 months for the products of runs RASH 6, LSDA 52 and RASH 14 (containing 9, 17 and 27%

theophylline respectively, in each case 100% amorphous) again lacked definite peaks, indicating no detectable drug crystallinity. An example DSC profile, for the RASH 14 sample, is shown in Figure 23.

In a similar experiment, the stabilities of four of the paracetamol/HPMC products were tested over a 24 month storage period. The storage conditions were as for the theophylline/EC systems. The 24 month DSC profiles for the products of experimental runs RASF 31, RASF 27, RASF 97 and RASF 40 (containing 19, 20, 21 and 29% paracetamol respectively, in each case 100% amorphous) indicated an absence of crystallinity. Figure 24 is an example DSC profile, for the RASF 40 sample.

Thus, coformulations according to the invention, made by a SEDS™ process, appear to possess excellent long term storage stability, with respect both to their physical properties and to re-crystallisation of the active substance.

With regard to the above stability data, it is of note that many of the systems tested were close to the point of inflexion on the graphs of crystallinity versus drug loading. In other words, they were systems containing the maximum possible drug loading before the onset of crystallinity. Other products of the invention, containing lower drug loadings, would if anything be more stable under the same storage conditions.

Solubility effects

A relationship was observed, in the systems containing the hydrophobic polymer ethyl cellulose, between the amorphous phase drug concentration and the total specific solubility parameters δ_s ($\delta_s = (\delta_p^2 + \delta_h^2)^{1/2}$ - see Table 1) of the reagents. Insofar as could be inferred from the systems studied, the trend was towards the maximum concentration of amorphous phase (and thus also the maximum drug:polymer interaction) being achieved when the δ_s of the drug and the polymer were equivalent or substantially so.

It appears that drug/polymer dispersion, and intermolecular/interpolymeric chain mixing and interaction, can be maximised by choosing the reagents so that $(\delta_s^d - \delta_s^p)$ is zero or close to zero (where δ_s^d and δ_s^p represent the total specific (ie, polar and hydrogen bonding) solubility parameters for the drug and polymer respectively). These systems would be expected to contain the maximum amount of amorphous phase drug, lower amorphous phase levels occurring as $(\delta_s^d - \delta_s^p)$ attained either a positive or a negative value.

Table 10 lists calculated values of $(\delta_s^d - \delta_s^p)$ for the systems studied, together with values of X% (mid-point and range).

Table 10

5

Drug/Polymer	$(\delta_s^d - \delta_s^p)$	X(%)	
		Midpoint	Range
Ascorbic acid/EC	20.7	12.5	10-15
Ascorbic acid/HPMC	16.8	37.5	35-40
Carbamazepine/EC	-0.2	25.0	20-30
Carbamazepine/HPMC	-4.1	32.5	25-40
Paracetamol/EC	4.8	6.0	1-12
Paracetamol/HPMC	0.9	30.0	25-35
Indomethacin/EC	-1.7	23.0	18-28
Indomethacin/HPMC	-5.6	40.0	35-45
Theophylline/EC	5.9	25.0	20-30
Theophylline/HPMC	2.0	12.5	5-20

The Table 10 data are plotted in Figures 25 and 26. The maximum amorphous phase contents found for drug/EC systems, with the exception of paracetamol/EC, seem to be in accord with the hypothesis (Figure 25), showing a maximum of approximately 27% amorphous content at $\delta_s^d - \delta_s^p = 0$. In contrast, for the drug/HPMC system (Figure 26), a minimum is observed at the zero point, with the paracetamol/polymer system again deviating from the trend.


The systems containing paracetamol deviate from the trends exhibited by the other drugs. Polar systems have a greater tendency to exhibit irregular solution behaviour. Furthermore, if a molecule contains at least two active groups with differing hydrogen bonding abilities, this can lead to anomalous solubility behaviour. Commonly referred to as the "chameleonic effect", this is a combined effect of the solubility parameter and solute-solvent and solvent-solvent hydrogen bonding. Paracetamol is known to form

irregular solutions in polar solvents [10-12] and contains the functional groups -OH and -NH-, which leads to varying behaviour dependent on the solvent environment.

It is of note that attempts to form amorphous paracetamol using conventional particle formation techniques have proved unsuccessful, this being attributed to the high crystallinity and crystal energy of the drug. However, using SEDS™ to coformulate paracetamol with for instance HPMC, a particulate product containing between 25 and 35% of the amorphous drug can be prepared.

10 Example II

This series of experiments demonstrates the coformulation, using SEDS™, of a cyclo-oxygenase-2 (COX-2) inhibitor of the formula (I):




((Z)-3-[1-(4-chlorophenyl)-1-(4-methanesulfonylmethylene)]-2,5-dihydrofuran-2-one) with:

15

(a) hydroxypropyl cellulose (HPC):

Structural Formula:



Where R is H or $[-CH_2-CH(CH_3)-]_mH$

and:

(b) "Poloxamer 237" (P-237), also known as Pluronic™ F87, which is a polyoxypropylene-polyoxyethylene block copolymer of the chemical formula
5 $\text{HO}(\text{C}_2\text{H}_4\text{O})_{64}(\text{C}_3\text{H}_6\text{O})_{37}(\text{C}_2\text{H}_4\text{O})_{64}\text{H}$.

The reagents used in the experiments were analytical or HPLC grade.

For (a), the solvent used was a mixture of DCM and ethanol (1:1), which could dissolve both the drug and the polymer together. The (HPC + drug) concentration was varied between 0.5 and 4.5% w/v and the DCM:ethanol ratio was altered where
10 appropriate to increase solution saturation. The ethanol helped to lower the viscosity of the HPC dispersion.

The operating conditions for (a) were 90 bar and between 50 and 70°C. Higher temperatures facilitated solvent extraction. CO₂ flows of up to 20 ml/min were used, with target solution flows of as low as 0.1 ml/min. The conditions for each experimental
15 run are summarised in Tables 11 and 12, appended.

For (b), the operating temperature was 35°C (due to the relatively low melting point of the polymer) and the pressure was varied between 75 and 100 bar. DCM was used as a solvent for both Compound (I) and the polymer together, with solution concentrations between 1 and 3% w/v. The CO₂ anti-solvent flowed at 18 ml/min and
20 the target solution at between 0.1 and 0.2 ml/min. Table 13 (appended) summarises the operating conditions for each run.

In both sets of experiments, nozzle outlet diameters of 100, 200, 400 and 750 µm were employed, and either a 50 ml or in some cases a 500 ml particle formation vessel.

Results & discussion – Compound (I) and HPC

25 The results are given in Tables 11 and 12, appended. The best yields and particle sizes were obtained in run 14, using 85% w/w of Compound (I) – this gave a 95% yield of free flowing rounded/plate-like particles with an average diameter of 3.8 µm (Figure 27, SEM taken at 4000x magnification). At 30% w/w HPC (run 17), a 96% yield was obtained but the particles were more flake-like and agglomerated, their average size being
30 13.1 µm. HPC concentrations of 50 and 80% w/w gave large (20.7 µm) coral-like

agglomerates (runs 21 (Figure 28, SEM taken at 2000x magnification) and 22). In all runs the recovery of Compound (I) was greater than 90%.

Generally, nozzle blockages were reduced at lower concentrations (eg, about 80% w/w or lower) of Compound (I). For some runs, a 50 ml vessel soon clogged with precipitated solids; a 500 ml vessel was substituted to eradicate this problem.

Particle agglomeration (and hence large particle sizes) could generally be reduced by decreasing the process throughput, for instance by reducing the concentration and/or flow rate of the drug/polymer solution (whilst still maintaining a near saturated solution).

Results & discussion – Compound (I) and P-237

The results are given in Table 13, appended. The smallest particles of pure Compound (I) were produced in run 38, using a 2% w/v target solution with a flow rate of 0.15 ml/min. These conditions were used to produce coformulations for dissolution testing, as well as a control batch of pure Compound (I).

The recovery of Compound (I) in all samples was 100%.

Degree of crystallinity

Products were subjected to DSC analysis to determine the degree of crystallinity in the Compound (I) present. The results, as a function of drug concentration, are shown in Tables 14 and 15 below, for the HPC and P-237 systems respectively, and are illustrated graphically in Figures 29 and 30 respectively.

**Table 14 -
Crystallinity levels in HPC systems**

<u>Concentration of Compound (I)</u> <u>(% w/w) (by HPLC)</u>	<u>ΔH_f coformulation</u> <u>I/g</u>	<u>% Crystallinity</u>
Unprocessed Compound (I)	96.1	100
100	94.2	98.1
100	94.0	97.8
100	94.2	98.0

88	78.0	92.2
86.7	75.1	90.2
79	73.9	97.3
78.6	77.7	102.9
64.5	54.9	88.6
50	26.9	56.1
43.6	31.7	75.7
26.7	5.1	20.0
20	0	0

Table 15 -
Crystallinity levels in P-237 systems

5

<u>Concentration of Compound (I)</u> <u>(% w/w) (by HPLC)</u>	<u>ΔH_f coformulation</u> <u>J/g</u>	<u>% Crystallinity</u>
Unprocessed Compound (I)	96.0	100
100	93.6	97.4
86.2	64.9	78.4
85	66.4	81.4
71.3	48.1	70.3
70.7	46.6	68.7
53.7	20.8	40.3
20	0	0.0

The results for both systems indicate that crystallinity is significantly reduced as polymer content increases. The reduction is nearly linear for the P-237 system, but for HPC a polymer content of at least 20% w/w is needed before crystallinity levels start to decrease. For both systems, a 100% amorphous product was achieved at drug loadings of 20% w/w or less.


Physical and chemical stability

A representative sample containing 20% w/w Compound (I) and 80% w/w P-237, produced using a SEDS™ process as described above, was stored for 13 months in a screw-top glass jar, under ambient conditions (10-27°C) and in the dark. At the end of this storage period the sample was found to have retained its initial physical properties, ie, it was still a free-flowing, easily handled powder containing discrete particles. It had also retained its 100% amorphous nature (assessed using DSC).

10

Example III

This series of experiments demonstrates the coformulation, using SEDS™, of a COX-2 inhibitor of the formula (II):



15

((Z)-3-[1-(4-bromophenyl)-1-(4-methylsulfonylphenyl)methylene]-dihydrofuran-2-one) with HPC.

Apparatus similar to that used in Examples I and II, but scaled up 10 fold, was used to carry out SEDS™ particle formation. Both Compound (II) and HPC (as used in Example II) were dissolved in acetone, at an optimum concentration of 2.0% w/v. The preferred operating temperature was 60°C and the pressure 120 bar. The optimum target solution flow rate was 1.0 ml/min, that for the supercritical carbon dioxide anti-solvent 200 ml/min. Products containing 10%, 20%, 30%, 50% and 70% w/w Compound (II)

were prepared using these conditions, the exact conditions for each run being summarised in appended Table 16.

For some runs, as indicated in the table, a lower molecular weight (80,000) grade of HPC was used.

5 Experiments were also carried out using DCM:ethanol (35:65 v/v) as the solvent, a solution concentration of 1.0% v/v, an operating temperature and pressure of 50°C and 90 bar respectively, a target solution flow rate of 1.0 ml/min and a supercritical carbon dioxide flow rate of 200 ml/min. The operating conditions for each run are summarised in Table 17, appended; a product containing 90% w/w Compound (II) was successfully
10 prepared.

Results & discussion

The results are given in the appended Tables 16 and 17. Sample crystallinity was assessed in each case by DSC; the results are shown in Table 18 below and represented
15 graphically in Figure 31 (plot of crystallinity against drug loading).

Table 18

<u>Compound (II)</u> <u>Conc. (% w/w)</u>	<u>Latent heat of fusion</u> <u>Coformulation</u> <u>(J/g)</u>	<u>% Crystallinity</u>	<u>Run N°</u>
Starting material	74.84	100	N/A
25	5.6	29.6	17
25	6.2	33.3	17
30	10	44.4	18
90	64.7	96.1	19
50	31.6	84.5	20
70	48.9	93.3	23
85	58.6	92.2	9
90	63.3	94	24
10	0	0	25
15	0	0	10
20	0	0	13

20

Thus, the products containing 20% w/w Compound (II) or less (run numbers 10, 13 and 25) had 0% crystallinity. After storage for approximately three months in screw top glass bottles, at ambient temperature (10-27°C) and in the dark, these samples were found to have retained their 100% amorphous nature. They were also still free-flowing, easily handled powders, as initially.

Example IV

This series of experiments demonstrates the coformulation, using SEDS™, of glibenclamide (1-{4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulphonyl}-3-cyclohexylurea, an anti-diabetic drug) and 75/25 DL-lactide-co-caprolactone (Birmingham Polymers, England).

Supercritical nitrogen was used as the anti-solvent, since supercritical carbon dioxide would plasticise the amorphous polymer excipient. The glibenclamide was dissolved in methylene chloride. The anti-solvent flow rates were between 15 and 25 litres min⁻¹, those for the drug solution between 0.05 and 0.1 ml min⁻¹. A 500 ml particle formation vessel was used, at an operating temperature of between 35 and 60°C and a pressure of 100 bar.

Results & discussion

Coformulations having drug:polymer ratios of between 1:1 and 9:1 were successfully produced under the above conditions. XRD analysis confirmed that although the glibenclamide raw material was crystalline, all of the SEDS™ products contained 100% amorphous phase drug.

For all of the coformulations, residual solvent levels (measured using headspace gas chromatography (Varian™)) were below 300 ppm, surprisingly low in view of the poor mass transfer properties of supercritical nitrogen relative to supercritical carbon dioxide.

30

Appendix

There now follow Tables 2-9 (Example I), 11-13 (Example II) and 16 and 17 (Example III), referred to above.

5

Ascorbic Acid Result Table 2

Experiment	Drug Conc. (%w/w)	Polymer Conc. (%w/w)	Polymer Conc. (%w/w)	Solvent	Solution Flow Rate (ml/min)	CO ₂ flow (ml/min)	Temp (°C)	Pressure (bar)	Nozzle tip diameter (µm)	Yield (%)	Comments	Morphology by SEM	DSC Peaks (SH - J/g)	% Drug in Product by UV (Wt %)
RASF79	0.2	EC 10cps	0.50	Ethanol	0.3	20	34	120	100	58	Fine particulate	ND	25.0	50.1
RASF80	0.5	EC 10cps	0.50	Ethanol	0.3	20	34	80	100	50	Fine particulate, large nozzle blocks	ND	108.4	50
RASF81	0.5	EC 10cps	0.50	Ethanol	0.3	20	34	80	100	ND	CO ₂ pump problem, fine particulate	ND	176.5	75
RASF82	0.4	EC 10cps	0.50	Ethanol	0.3	20	34	80	100	63	Fine particulate	ND	123.7	57.1
RASF83	0.0	EC 10cps	0.60	Ethanol	0.3	20	34	80	100	73	Fine particulate	ND	2	5
RASF86 (SW)	0.1	EC 7cps	0.50	Methanol	0.2	20	34	80	100	62	Fine white particulate	ND	372	3.2
RASF97 (SW)	0.1	EC 7cps	0.50	Methanol	0.2	20	34	80	100	40	Fine white particulate	ND	29.24	17.2
RASF98 (SW)	0.2	EC 7cps	0.50	Methanol	0.2	20	34	80	100	29	Fine white particulate	ND	51.29	21.1
RASF99 (SW)	0.2	EC 7cps	0.50	Methanol	0.2	20	34	80	100	40	Fine white particulate	ND	64	39.3
LSDA148	0.2	HPMC 3cps	0.50	Ethanol / DCM (1:1)	0.3	20	34	80	100	61	Fine white powder	Aggregates	None	24
LSDA19	0.5	HPMC 3cps	0.50	Ethanol / DCM (1:1)	0.3	20	34	80	100	71	Fine white powder	Aggregates	96	48
LSDA20	1.0	HPMC 3cps	0.50	Ethanol / DCM (1:1)	0.3	20	34	80	100	81	Fine white powder	Aggregates	123	69
LSDA21	1.5	HPMC 3cps	0.50	Ethanol / DCM (1:1)	0.3	20	34	80	100	41	Fine off-white powder	Aggregates (0.5-0.5µm)	182	74
LSDA31	4.5	EC 10cps	0.50	Ethanol	0.3	20	34	80	100	58	Fine off-white powder	ND	226	86
LSDA32	4.5	EC 10cps	0.50	Ethanol	0.3	20	34	80	100	98	Fine off-white powder	ND	221	91
LSDA33	4.5	EC 10cps	0.50	Ethanol	0.3	20	34	80	100	64	Fine off-white powder	ND	222	91
LSDA34	2.0	EC 10cps	0.50	Ethanol	1.3	20	34	80	100	63	Fine off-white powder	ND	222	73
LSDA49	0.1	EC 10cps	0.50	Ethanol	0.3	20	34	80	100	47	Fine white powder	ND	24	18
LSDA50	0.1	EC 10cps	0.50	Ethanol	0.3	20	34	80	100	66	Fine white powder	ND	None	5

NA - Not applicable, ND - Not determined

All experiments used a two component nozzle

Carbamazepine Results Table 3

Experiment	Drug Conc. (%w/v)	Polymer	Polymer Conc. (%w/v)	Solvent	Solution Flow Rate (ml/min)	Pressure (bar)	CO ₂ flow (ml/min)	Temp. °C	Nozzle tip diameter (µm)	Yield (%)	Product Description	Size (µm, b.v. SEM)	Morphology: (b.v. SEM)	DSC Peaks (ΔH/Jg)	% Drug in Product by UV/Wt(%)
LSDA6	2.0	N/A	0	Ethanol	0.2	80	20	50	100	61	Fine white powder	ND	Acicular with some agglomerates	101	NA
LSDA7	0.5	HPMC	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	100	38	Fine white powder	ND	Acicular with some agglomerates	19	41
LSDA8	0.5	HPMC	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	58	Fine white powder	ND	Acicular	47	59
LSDA9	0.25	HPMC	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	48	Fine white powder	ND	Acicular with some agglomerates	22	42
LSDA10	1.0	HPMC	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	85	Fine white powder	ND	Acicular	79	64
LSDA11	0.167	HPMC	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	45	Fine white powder	0.5 x 0.5	Aggregates with some acicular	None	25
LSDA12	1.5	HPMC	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	95	Fine white powder	ND	Acicular	87	87
LSDA13	0.5	EC Tops	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	89	Fine white powder	ND	Acicular	26	43
LSDA14	0.25	EC Tops	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	80	Fine white powder	ND	Acicular	18	29
LSDA15	1.0	EC Tops	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	94	Fine white powder	ND	Acicular	53	60
LSDA16	0.167	EC Tops	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	70	Fine white powder	ND	Acicular	None	74
LSDA17	1.5	EC Tops	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	89	Fine white powder	ND	Acicular with some agglomerates	58	69
LSDA18	0.133	EC Tops	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	85	Fine white powder	ND	ND	None	24
LSDA20	1.167	EC Tops	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	94	Fine white powder	ND	ND	68	70
LSDA22	0.215	EC Tops	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	500	49	Fine white powder	ND	ND	13	30
LSDA34	0.215	HPMC	0.5	Ethanol / DCM (1:1)	0.2	80	20	50	200	82	Fine white powder	ND	ND	None	28

A two-component nozzle was used in all experiments

NA - Not applicable, ND - Not determined

Indomethacin Result Table 4

Experiment	Drug Conc. (mg/ml)	Drug Conc. (mg/ml)	Polymer Conc. (mg/ml)	Polymer Conc. (mg/ml)	Solvent Flow Rate (ml/min)	CO ₂ Flow Rate (ml/min)	Temp (°C)	Pressure (bar)	Nozzle tip diameter (mm)	Yield (%)	Product Description	Size (µm, by SEM)	Morphology (by SEM)	OSC Analysis by DSC (°C)	% Drug in Product by LY (Wt %)
RASE1	Ethanol	2	NA	0	0.2	15	50	100	100	81	Mass of fine particles	30 ± 1	Flakes	ND	NA
RASE2	Acetone	2	NA	0	0.2	15	50	100	100	75	Mass of fine particles	15 ± 2	Acicular	ND	NA
RASE18	Ethanol / DCM (1:1)	0.5	HPMC	0.5	0.2	20	37	80	500	39	Free off-white particles	<0.1 ± 0.1	Aggregates	None	13
RASE19	Ethanol / DCM (1:1)	0.25	HPMC	0.75	0.2	20	37	80	500	71	Free off-white particles	<0.1 ± 0.1	Aggregates	None	13
RASE20	Ethanol / DCM (1:1)	0.25	HPMC	0.75	0.2	20	37	100	500	75	Free off-white particles	0.1 ± 0.1	Aggregates	None	9
RASE21	Ethanol / DCM (1:1)	0.25	HPMC	0.75	0.2	20	37	80	500	42	Pale yellow fine particles	1 ± 1	Amorphous	None	27
RASE22	Ethanol / DCM (1:1)	0.25	HPMC	0.75	0.2	20	37	80	500	63	Pale yellow fine particles	0.5 ± 0.5	Aggregates	None	17
RASE23	Ethanol / DCM (1:1)	0.5	HPMC	0.5	0.2	20	37	80	500	64	Free off-white particles	0.5 ± 10 & 1 ± 1	Acetate & amorphous Aggregates, acicular & fibers	0.7	35
RASE24	Ethanol / DCM (1:1)	0.5	HPMC	0.5	0.2	20	37	80	500	39	Very fine white particles with yellowish	Wide variations	Aggregates & fibers	43.0	42
RASE25	Ethanol / DCM (1:1)	0.5	HPMC	0.5	0.2	20	37	80	500	31	Free off-white particles	100 ± 0.5	Aggregates & fibers	0.1	22
RASE26	Ethanol / DCM (1:1)	0.5	HPMC	0.5	0.2	20	37	80	500	75	Free white particles with on-tail	50, 150, 300 ± 1	Tabular, acicular & fibers	<20 (155°C) 13 (166°C)	89
RASE27	Ethanol / DCM (1:1)	0.5	HPMC	0.5	0.2	20	37	80	500	64	Free off-white particles	Wide variations	Aggregates & fibers	0.3	38
RASE28	Ethanol / DCM (1:1)	0.5	HPMC	0.5	0.2	20	37	80	500	71	Free off-white particles	0.5 ± 0.5	Amorphous	None	13
RASE29	Ethanol / DCM (1:1)	0.5	HPMC	0.5	0.2	20	37	80	500	72	Free off-white particles	0.1 ± 0.1	Amorphous	None	5
RASE30	Ethanol / DCM (1:1)	0.5	HPMC	0.5	0.2	20	37	80	500	73	Free off-white particles	0.1 ± 0.1	Amorphous aggregates	None	10
RASE31	Ethanol / DCM (1:1)	0.167	HPMC	0.833	0.2	20	37	80	500	52	Free off-white particles	0.3 ± 0.2	Amorphous aggregates	None	14
RASE32	Ethanol / DCM (1:1)	0.167	HPMC	0.833	0.2	20	37	80	500	61	Free off-white particles	0.5 ± 0.2	Amorphous aggregates	None	13
RASE33	Ethanol / DCM (1:1)	0.33	HPMC	0.667	0.2	20	37	80	500	64	Free off-white particles	Wide variations	Aggregates, acicular & fibers	12.2	31
RASE34	Ethanol / DCM (1:1)	0.33	HPMC	0.667	0.2	20	37	80	500	61	Free off-white particles	30 ± 0.3	Amorphous & fibers	29.1	67
RASE35	Ethanol / DCM (1:1)	0.33	HPMC	0.667	0.2	20	37	80	500	40	Free off-white particles	0.1 ± 0.1	Amorphous aggregates	None	11
RASE36	Ethanol / DCM (1:1)	0.33	HPMC	0.667	0.2	20	37	80	500	39	Free off-white particles	0.05 ± 0.05	Amorphous aggregates	None	17
RASE37	Ethanol / DCM (1:1)	0.33	HPMC	0.667	0.2	20	37	80	500	75	Pale yellow fine particles	0.5 ± 0.5 & 0.5 ± 0.5	Aggregates, acicular & fibers	19.6	42
RASE38	Ethanol / DCM (1:1)	0.33	HPMC	0.667	0.2	20	37	80	500	74	Pale yellow fine particles	20 ± 0.5, 10 ± 0.2	Amorphous (110°C) acicular & fibers	20.7	31
RASE39	Ethanol / DCM (1:1)	0.41	HPMC	0.59	0.2	20	37	80	500	51	Free off-white particles	<0.1 ± 0.1	Amorphous aggregates	None	12

NA - Not applicable. ND - Not determined

A two-component mixture was used in all experiments

Indomethacin Result Table 5

Experiment	Drug Solvent	Drug Conc. (wt.%)	Polymer	Polymer Conc. (wt.%)	Polymer Sol. (wt.%)	Solvent Flow Rate (ml/min)	CO ₂ Temp. (°C)	Pressure (bar)	Head up diameter (mm)	Yield (%)	Product Description	Size (µm, by SEM)	Morphology (by SEM)	DSC Peaks (J/g)	% Drug in UV (wt.%)
RASE18	Ethanol	0.5	EC (100)	0.5	Ethanol	0.1	20	37	80	100	12	100 ± 10	Amorphous pellet chunks	None	34
RASE19	Ethanol	0.5	EC (100)	0.5	Ethanol	0.05	20	37	80	100	19	100 ± 10	Amorphous pellet chunks	None	46
RASE60	Ethanol	0.75	EC (100)	0.75	Ethanol	0.1	20	37	80	100	19	100 ± 10	Amorphous pellet chunks	None	41
RASE63	Ethanol	0.25	PVP (100)	0.25	(1:1) Ethanol / Chloroform	0.2	20	37	80	100	31	100 ± 10	Amorphous pellet chunks	None	48
RASE61	Ethanol	0.75	PVP (100)	0.25	Chloroform	0.2	20	37	80	100	16	100 ± 10	Amorphous pellet chunks with needles, tablets & microphases	None	61
RASE64	Ethanol	0.75	PVP (100)	0.25	(1:1) Ethanol / Chloroform	0.2	20	30	80	100	38	50 ± 50, 10 ± 0.5, 10 ± 2.8, 5 ± 3	Amorphous pellet chunks	21.3	79
RASE64	Ethanol	0.75	PVP (100)	0.25	(1:1) Ethanol / Chloroform	0.2	20	30	80	100	26	250 ± 200	Amorphous pellet chunks	None	51
RASE64	Ethanol	0.75	PVP (100)	0.25	(1:1) Ethanol / Chloroform	0.2	20	30	80	100	13	100 ± 100	Amorphous pellet chunks	NA	17
RASE64	Ethanol	0.75	PVP (100)	0.25	(1:1) Ethanol / Chloroform	0.2	20	37	80	100	10	100 ± 100	Amorphous pellet chunks	None	20
RASE64	Ethanol	0.75	PVP (100)	0.25	(1:1) Ethanol / Chloroform	0.2	20	30	80	100	8	200 ± 150	Amorphous pellet chunks	None	16
RASE64	Ethanol	0.75	PVP (100)	0.25	(1:1) Ethanol / Chloroform	0.2	20	37	80	100	73	50 ± 50, 10 ± 0.5, 3 ± 2, 1 ± 1	Amorphous pellet chunks with needles, tablets & microphases	62.1	86
RASE77	Ethanol	1.8	PVP (100)	0.2	(1:1) Ethanol / Chloroform	0.2	20	37	80	100	64	50 ± 50, 10 ± 0.5, 6 ± 2, 2 ± 2	Amorphous pellet chunks with needles, tablets & microphases	62.1	81
RASE77	Ethanol	1.8	PVP (100)	0.2	(1:1) Ethanol / Chloroform	0.2	20	37	80	100	43	50 ± 50, 10 ± 0.5, 2 ± 1, 0.5 ± 0.2	Amorphous pellet chunks with needles, tablets & microphases	73.1	67
RASE77	Ethanol	0.75	PVP (100)	0.25	(1:1) Ethanol / Chloroform	0.2	20	30	80	100	13	50 ± 50, 10 ± 0.5, 2 ± 2, 0.5 ± 1.0	Amorphous pellets with needles, tablets & microphases	57.2	76
RASE77	Ethanol	0.75	PVP (100)	0.25	(1:1) Ethanol / Chloroform	0.2	20	37	80	100	81	20 ± 5, 5 ± 0.5, 4 ± 2, 1 ± 1	Amorphous pellets with needles, tablets & microphases	29.1	76
RASE77	Ethanol	0.75	PVP (100)	0.25	(1:1) Ethanol / Chloroform	0.2	20	40	80	100	30	ND	ND	None	10
LSDA17	Ethanol	0.148	EC (50)	0.5	Ethanol DCM	0.2	20	37	80	100	11	ND	ND	None	22
LSDA18	Ethanol	0.170	EC (50)	0.5	Ethanol DCM	0.2	20	30	80	100	17	ND	ND	None	20
LSDA19	Ethanol	0.5	EC (50)	0.5	Ethanol DCM	0.3	20	34	80	100	ND	ND	ND	None	34
LSDA20	Ethanol	1.517	EC (50)	0.5	Ethanol	0.2	20	34	80	100	10	ND	ND	None	13
LSDA41	Ethanol	0.339	EC (50)	0.5	Ethanol	0.2	12	34	80	100	89	ND	ND	48	85
LSDA43	Ethanol	1.515	EC (50)	0.5	Ethanol	0.1	15	36	80	100	67	ND	ND	37	50
LSDA44	Ethanol	0.5	EC (50)	0.5	Ethanol	0.1	15	30	80	100	84	ND	ND	51	79
LSDA45	Ethanol	1.0	EC (50)	0.5	Ethanol	0.1	15	30	80	100	1	ND	ND	31	42
LSDA46	Ethanol	0.341	EC (50)	0.5	Ethanol	0.1	15	30	80	100	1	ND	ND	31	42

NA: Not applicable. ND: Not determined

A two-component result is used in all experiments

Ketoprofen Result Table 6

Experiment	Drug Conc. (%w/v)	Polymer	Polymer Conc'n (%w/v)	Solvent	Solution Flow Rate (ml/min)	CO ₂ flow (ml/min)	Temp (°C)	Pressure (bar)	Nozzle tip diameter (µm)	Yield (%)	Product Description	Size (µm, by SEM)	Morphology (by SEM)	DSC Peaks (ΔH - J/g)	% Drug in Product by UV (wt %)
RASG1	0.5	HPM1C 3cps	0.5	Ethanol / DCM (1:1)	0.1	20	37	80	200	47	Fine white particulate	<0.1 x 0.1	Amorphous aggregate	None	8
RASG2	0.5	HPM1C 3cps	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	200	42	Off-white particulate	0.2 x 0.3	Amorphous	0.1	39
RASG3	0.5	HPM1C 3cps	0.5	Ethanol / DCM (1:1)	0.2	20	37	30	200	40	Fine white particulate	0.2 x 0.2	Amorphous aggregate	None	11
RASG4	0.5	HPM1C 3cps	0.5	Ethanol / DCM (1:1)	0.2	20	37	80	200	45	Fine white particulate	0.2 x 0.2	Amorphous aggregate	None	10
RASG5	0.5	HPM1C 3cps	0.5	Ethanol / DCM (1:1)	0.1	12	37	80	200	38	Fine white particulate	0.2 x 0.2	Amorphous aggregate	None	6
RASG6	0.5	HPM1C 3cps	0.5	Ethanol / DCM (1:1)	0.1	20	37	100	200	42	Fine white particulate	0.1 x 0.1	Amorphous aggregate	None	4
RASG7	0.5	HPM1C 3cps	0.5	Ethanol / DCM (1:1)	0.1	20	37	80	500	38	Fine white particulate	0.2 x 0.2	Amorphous aggregate	None	8
RASG8	5	NA	0	Ethanol	0.2	15	50	100	200	0	No product	NA	NA	NA	NA
RASG9	5	NA	0	DCM	0.2	15	37	80	200	0	No product	NA	NA	NA	NA
RASG10	5	NA	0	Acetone	0.2	15	37	80	200	0	No product	NA	NA	NA	NA
RASG11	0.5	HPM1C 3cps	0.5	Ethanol / DCM (1:1)	0.2	20	50	80	200	39	Fine white particulate	0.3 x 0.3	Amorphous aggregate	None	20
RASG12	0.5	HPM1C 3cps	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	100	47	Fine white particulate	0.1 x 0.1	Amorphous aggregate	None	12
RASG13	0.5	HPM1C 3cps	0.5	Ethanol / DCM (1:1)	0.2	20	50	80	100	45	Fine white particulate	0.3 x 0.3	Amorphous aggregate	None	22

NA - Not applicable, ND - Not determined

All experiments used a two component nozzle

Ketoprofen Result Table 7

Experiment	Drug Conc. (%w/v)	Polymer	Polymer Conc'n (%w/v)	Solvent	Solution Flow Rate (ml/min)	CO ₂ flow (ml/min)	Temp (°C)	Pressure (bar)	Nozzle tip diameter (µm)	Yield (%)	Product Description	Size (µm, by SEM)	Morphology (by SEM)	DSC Peaks (ΔH - J/g)	% Drug in Product by UV (Wt %)
RASG14	0.5	EC 7cps	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	200	0	No product	NA	NA	NA	NA
RASG15	0.5	EC 7cps	0.5	Ethanol / DCM (1:1)	0.1	20	37	80	200	10	White cobs	ND	ND	ND	NA
LSDA22	0.5	HPMC	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	100	31	Fine white powder	NA	Aggregates	None	22
LSDA23	0.167	HPMC	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	200	45	Fine white powder	NA	Aggregates	None	7
LSDA24	0.25	HPMC	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	200	39	Fine white powder	NA	Aggregates	None	11
LSDA25	1.0	HPMC	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	200	7	Fine white powder	NA	Aggregates	None	25
LSDA26	1.5	HPMC	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	200	0	ND	ND	Aggregates	1	ND
LSDA27	4.5	HPMC	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	200	0	No product	NA	NA	NA	NA
LSDA28	4.5	HPMC	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	200	0	No product	NA	NA	NA	NA
LSDA29	4.5	HPMC	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	200	3	Fine white powder	ND	ND	None	49
LSDA30	4.5	HPMC	0.5	Ethanol / DCM (1:1)	0.1	20	50	80	200	2	Fine white powder	ND	ND	None	52
LSDA36	4.5	HPMC	0.5	Ethanol / DCM (1:1)	0.05	10 N	35	80	200	1	Fine white powder	ND	ND	83	84
LSDA39	2.25	HPMC	0.25	Ethanol / DCM (1:1)	0.05	20 N	50	80	200	0	No product	NA	NA	NA	NA

All experiments used a two component nozzle

NA - Not applicable, ND - Not determined

N - In these two experiments, nitrogen was substituted for CO₂ (flows are in l/min measured at ambient conditions)

Paracetamol Result Table 8

Experiment	Drug Conc. (%w/v)	Drug Solvent	Polymer	Polymer Conc. (%w/v)	Polymer Solvent	Solution Flow Rate (ml/min)	CO ₂ flow (ml/min)	Temp (°C)	Pressure (bar)	Nozzle tip diameter (µm)	Yield (%)	Comments	Morphology by SEM	DSC Peaks (ΔH, J/g)	% Drug in Product by UV (% w/w)
RASF77	0.17	Ethanol / DCM (1:1)	HPMC 7cps	0.50	Ethanol / DCM (1:1)	0.1	20	30	120	510	69	Fine powder	10µm diameter irregular chunks	None	20
RASF70	0.17	Ethanol / DCM (1:1)	HPMC 15cps	0.50	Ethanol / DCM (1:1)	0.1	20	30	120	none	35	Fine powder	spheres, some chunks	None	4
RASF71	0.17	Ethanol / DCM (1:1)	HPMC 15cps	0.50	Ethanol / DCM (1:1)	0.1	20	37	80	none	63	Fine powder	spheres, some chunks	None	19
RASF72	0.50	Ethanol / DCM (1:1)	HPMC 7cps	0.50	Ethanol / DCM (1:1)	0.1	20	37	80	510	60	Fine particles produced with some hard lumps	100µm needles & spheres	83.0	ND
RASF74	0.50	Ethanol / DCM (1:1)	HPMC 7cps	0.50	Ethanol / DCM (1:1)	0.1	2.5	37	80	510	ND	Particulates with extrude on nozzle	10µm irregular spheres	None	ND
RASF78	0.17	Ethanol / DCM (1:1)	HPMC 7cps	0.50	Ethanol / DCM (1:1)	0.1	20	30	120	200	57	Fine powder	10µm irregular chunks	None	17
RASF70	0.17	Ethanol / DCM (1:1)	HPMC 7cps	0.50	Ethanol / DCM (1:1)	0.1	10	30	120	200	62	Fine powder	200nm spheres	None	29
RASF73	0.17	Ethanol / DCM (1:1)	HPMC 6cps	0.50	Ethanol / DCM (1:1)	0.1	20	30	120	200	60	Fine powder (large pressure fluctuations)	w-3 like spheres	0	17
RASF96 (RS)	0.1	Ethanol / DCM (1:1)	EC 7cps	0.50	Methanol	0.2	20	34	80	100	65	Fine powder	ND	64	48.5
RASF97 (RS)	0.17	Ethanol / DCM (1:1)	EC 7cps	0.50	Methanol	0.2	20	34	80	100	66	Fine powder	ND	None	21
RASF98 (RS)	0.25	Ethanol / DCM (1:1)	HPMC 7cps	0.50	Ethanol / DCM (1:1)	0.2	20	34	80	100	48	Fine powder	ND	0.2	28
RASF99 (RS)	1.00	Ethanol / DCM (1:1)	HPMC 7cps	0.50	Ethanol / DCM (1:1)	0.2	20	34	80	100	74	Fine powder	ND	105	72
RASF103 (RS)	2.00	Ethanol / DCM (1:1)	HPMC 7cps	0.50	Ethanol / DCM (1:1)	0.2	20	34	80	100	76	Fine powder	ND	125.5	82
RASF104 (RS)	0.21	Ethanol / DCM (1:1)	EC 7cps	0.50	Ethanol / DCM (1:1)	0.2	20	34	80	100	ND	Fine powder	ND	15.8	34
RASF105 (RS)	0.09	Ethanol / DCM (1:1)	EC 7cps	0.50	Ethanol / DCM (1:1)	0.2	20	34	80	50	50	Fine powder	ND	16.4	12
LSDA35	0.026	Ethanol	EC 10cps	0.5	Ethanol	0.1	20	37	100	200	46	Fine white powder	ND	3	0
LSDA37	0.026	Ethanol / DCM (1:1)	HPMC	0.5	Ethanol / DCM (1:1)	0.1	20	30	120	200	44	Fine white powder	ND	None	2
LSDA46	0.317	Ethanol	EC 10cps	0.5	Ethanol	0.1	20	37	100	200	53	Fine white powder	ND	74	19
LSDA47	0.066	Ethanol / DCM (1:1)	HPMC	0.5	Ethanol / DCM (1:1)	0.1	20	30	120	200	64	Fine white powder	ND	None	2
LSDA48	0.079	Ethanol	EC 10cps	0.5	Ethanol	0.1	20	37	100	200	9	Fine white powder	ND	3	1
LSDA51	0.079	Ethanol	EC 7cps	0.5	Ethanol	0.1	20	37	100	200	16	Fine white powder	ND	None	1

All experiments used a two component nozzle

NA - Not applicable, ND - Not determined

Theophylline Result Table 9

Experiment	Dry Conc'n (g/kg)	Polymer	Polymer Conc'n (g/kg)	Solvent	Solvent Flow Rate (ml/min)	CO ₂ Flow Rate (ml/min)	Temp (°C)	Pressure (bar)	Nozzle tip diameter (mm)	Yield (%)	Product Description	Size (µm, by SEM)	Morphology (by SEM)	DSC Peak °C (4th - 1st)	% Drug in Product by UV (wt-%)
RASH1	0.17	HPMC 3cpi	0.5	Ethanol / DCN (1:1)	0.1	20	37	80	200	60	Fine white particulate	< 1 x 0.1	Amorphous aggregate	None	3
RASH2	0.17	HPMC 3cpi	0.5	Ethanol / DCN (1:1)	0.1	20	50	80	200	71	Fine white particulate	20 x 20 x 0.1 x 0.1	Amorphous aggregate / tubular	None	28
RASH3	0.17	HPMC 3cpi	0.5	Ethanol / DCN (1:1)	0.2	20	37	80	200	71	Fine white particulate	0.1 x 0.1	Amorphous aggregate	None	5
RASH4	0.5	HPMC 3cpi	0.5	Ethanol / DCN (1:1)	0.1	20	37	80	200	78	Fine white particulate, some cobs	< 1 x 0.1 / 20 x 5 / 30 x 1	Amorphous aggregate / platy / acicular	44.5	38
RASH5	0.5	HPMC 3cpi	0.5	Ethanol / DCN (1:1)	0.1	20	50	80	200	85	Fine white particulate, some cobs	< 0.1 x 0.1 / 40 x 30 / 20 x 1	Amorphous aggregate / platy / acicular	78.2	46
RASH6	0.5	EC 7cpi	0.5	Ethanol	0.2	20	37	80	200	13	Fine white particulate, some cobs	5 x 5	Amorphous aggregate	None	9
RASH7	0.5	EC 7cpi	0.5	Ethanol	0.1	20	37	80	200	30	Fine white particulate	5 x 5	Amorphous aggregate	None	5
RASH8	0.33	HPMC 3cpi	0.5	Ethanol / DCN (1:1)	0.1	20	37	80	200	49	Fine white particulate, some cobs	0.1 x 0.1 / 20 x 5 / 5 x 0.5	Amorphous aggregate / platy / acicular	18.3	21
RASH9	0.33	HPMC 3cpi	0.5	Ethanol / DCN (1:1)	0.1	20	50	80	200	74	Fine white particulate, some cobs	0.5 x 0.5 / 20 x 10 / 20 x 1	Amorphous aggregate / platy / acicular	41.2	59
RASH10	0.17	EC 7cpi	0.5	Ethanol	0.1	20	50	80	200	41	Fine white particulate	2 x 2 / 70 x 50	Amorphous aggregate / platy	None	28
RASH11	0.5	EC 7cpi	0.5	Ethanol / DCN (1:1)	0.2	20	34	80	100	47	Fine white particulate	1 x 1 / 1 x 6	Amorphous aggregate / platy	30.3	34
RASH12	0.5	EC 7cpi	0.5	Ethanol / DCN (1:1)	0.1	20	50	80	100	78	Fine white particulate	2 x 10	Amorphous aggregate / platy	55.2	48
RASH13	0.17	EC 7cpi	0.5	DCN (1:1)	0.3	20	50	80	100	43	Fine white particulate	2 x 2 / 6 x 2	Amorphous aggregate / platy	ND	17
RASH14	0.25	EC 7cpi	0.5	DCN (1:1)	0.3	20	50	80	100	49	Fine white particulate	2 x 2 / 8 x 2	Amorphous aggregate / platy	None	27
RASH15	1.0	EC 7cpi	0.5	DCN (1:1)	0.3	20	50	80	100	92	Fine white particulate	ND	ND	77.3	67
LSDA41	0.33	HPMC 3cpi	0.5	Ethanol / DCN (1:1)	0.2	20	37	80	100	44	Fine white powder	ND	ND	None	35
LSDA44	0.056	EC 7cpi	0.5	Ethanol / DCN (1:1)	0.2	20	50	80	200	6	Fine white powder	ND	ND	None	7
LSDA45	0.056	HPMC 3cpi	0.5	DCN (1:1)	0.2	20	50	80	200	33	Fine white powder	ND	ND	None	2
LSDA52	0.125	EC 7cpi	0.5	DCN (1:1)	0.2	20	50	80	200	ND	ND	ND	ND	None	17
LSDA53	0.125	EC 7cpi	0.5	Ethanol / DCN (1:1)	0.2	20	50	80	200	76	Fine white powder	ND	ND	16.0	20
LSDA55	0.172	EC 7cpi	0.5	Ethanol / DCN (1:1)	0.3	20	50	80	100	58	Fine white powder	ND	ND	7.9	26
LSDA56	1.515	HPMC 3cpi	0.5	DCN (1:1)	0.1	20	50	80	200	14	Fine white powder	ND	ND	83.7	71

NA - Not applicable. ND - Not determined

All experiments used a two component nozzle

Table 11 - Compound (I) and HPC

Run No	Solvent	Soln. Conc. (wt%)	D:P Ch:Drug HPLC	CO ₂ Flow (ml/min)	Soln. Flow (ml/min)	P (bar)	I (°C)	AP (bar)	Nozzle Size (mm)	Yield (%)	Particle Size (S) (µm)	SEM Morphology / Description	Comments
1	1:1 v/v DCM/EtOH	4.5	89:11	18.0	0.2	90	65	300	0.1	73	16.2 (A)	Clusters of rounded particles < 2µm	Small nozzle tip causing large pressure build up
2	1:1 v/v DCM/EtOH	4.5	89:11	18.0	0.2	90	52	300	0.1	72	3.3 (A)	Clusters of rounded particles < 2µm and needles < 5µm	New 0.1mm tip. Blockages again causing processing problems.
3	1:1 v/v DCM/EtOH	3.5	86:14 (86.7)	18.0	0.2	90	60	280	0.1	70	7.2 (A)	Clusters of rounded particles < 2µm. Some needles.	Large pressure build up
4	1:1 v/v DCM/EtOH	3.5	86:14 (78.6)	18.0	0.2	90	70	250	0.2	69	18.7 (A)	Clusters of rounded particles < 2µm. Some needles.	Larger nozzle tip does not reduce pressure build up. Higher temp. HPC only using same conditions. A tiny amount of lumps produced
5	1:1 v/v DCM/EtOH	0.5	0:100	18.0	0.2	90	70	30	0.2	4	-	Clusters of rounded particles < 2µm	Drug only at higher temperature conditions.
6	1:1 v/v DCM/EtOH	3.0	100:0	18.0	0.2	90	70	300	0.2	47	2.8	Clusters of rounded particles < 2µm	Reduced nozzle blockages with higher polymer content.
7	1:1 v/v DCM/EtOH	1.0	50:50 (43.8)	18.0	0.2	90	70	15	0.2	24	-	Clusters/agglomerates of flake like particles < 2µm	Lower nozzle blockages. Particles are more agglomerated
8	1:1 v/v DCM/EtOH	0.7	30:70 (26.7)	18.0	0.2	90	70	10	0.2	40	-	Agglomerated flake/plates	Repeat of run 7
9	1:1 v/v DCM/EtOH	1.0	50:50	18.0	0.2	90	70	10	0.2	53	-	Clusters/agglomerates of flake like particles < 2µm	Large nozzle blockages. Solvent modified to increase saturation
10	35:65 v/v DCM/EtOH	1.0	100:0	20.0	0.2	90	67	120	0.2	72	2.6	Clusters of rounded particles < 2µm	Sample very agglomerated, hence larger particle size results
11	35:65 v/v DCM/EtOH	1.0	85:15	20.0	0.2	90	70	110	0.2	72	22.1	Small particles < 2 µm, highly agglomerated.	Large nozzle blockages. Lower soln flow has reduced particle size
12	35:65 v/v DCM/EtOH	1.0	85:15	20.0	0.1	90	70	200	0.2	73	3.8	Clusters of rounded/plate like particles < 2µm	High concentration for greater throughput. High yield
13	1:1 v/v DCM/EtOH	3.5	89:11	20.0	0.2	90	70	150	0.2	97	10.8	Agglomerated rounded/plate like particles < 2µm	Repeat of run 12
14	35:65 v/v DCM/EtOH	1.0	85:15 (79.0)	20.0	0.1	90	70	150	0.2	95	3.8	Clusters of rounded/plate like particles < 2µm	Reduced nozzle blockages with higher HPC content.
15	35:65 v/v DCM/EtOH	1.0	70:30	20.0	0.2	90	70	45	0.2	84	17.7	Agglomerated plate like particles < 3µm, some small needles	Pure drug sample to be used as a control for dissolution.
16	35:65 v/v DCM/EtOH	1.0	100:0	20.0	0.1	90	70	150	0.2	95	2.5	Agglomerated rounded particles < 2µm. No agglomeration.	Particles size smaller than in run 15.
17	35:65 v/v DCM/EtOH	1.0	70:30 (64.5)	20.0	0.1	90	70	60	0.2	96	13.1	Agglomerated plate like particles < 2µm, numerous small needles	Reduced solution flow?

Table 12 - Compound (I) and HPC

Run No.	Solvent	Soln. Conc. (w/v)	Dr.F. Cal.Dr. (HPLC)	CO ₂ Flow (ml/min)	Soln. Flow (ml/min)	P (bar)	T (°C)	ΔP (bar)	Nozzle Size (mm)	Yield (%)	Particle Size (S) (μm)	SEM Morphology/Description	Comments
18	35:65 v/v DCM/EtOH	1.0	50:50	20.0	0.1	90	70	12	0.2	73	-		CO ₂ ran out mid run leaving wd material.
19	25:75 v/v DCM/EtOH	1.0	50:50 (43.6)	20.0	0.1	90	70	40	0.2	88	28.4	Agglomerated/fused plate like particles	Solvent modified to achieve maximum saturation.
20	20:80 v/v DCM/EtOH	1.0	50:50	20.0	0.1	90	70	30	0.2	-	18.0	Agglomerated/fused plate like particles	Drug solution crashed out mid run. Run abandoned
21	25:75 v/v DCM/EtOH	1.0	50:50 (53.7)	20.0	0.1	90	70	45	0.2	74	20.7	Agglomerated/fused plate like particles	500 ml vessel used to stop material from plugging the nozzle region.
22	20:80 v/v DCM/EtOH	1.0	20:80 (17.9)	20.0	0.1	90	70	12	0.2	27	-	Fused strings of large, > 10 μm, rounded, particles	500ml vessel. Very low yield.
23	35:65 v/v DCM/EtOH	1.0	95:5	20.0	0.1	90	70	50	0.2	90	2.8	Clusters of small rounded / plate like particles < 2 μm	Addition of 5% HPC may improve dissolution further. Small particles
24	35:65 v/v DCM/EtOH	1.0	85:15	20.0	0.2	130	60	25	0.2	81	15.3	Larger angular particles. Some agglomeration	New P + T conditions reduce ΔP but particle morphology changes

Table 13 - Compound (I) and P-237

Run No.	Solvent	Soln. Conc. (wt %)	D:P (Chloroform/Fluorocarbon)	CO ₂ Flow (ml/min)	Soln. Flow (ml/min)	P (bar)	T (°C)	ΔP (bar)	Nozzle Size (mm)	Yield (%)	Particle Size (μm)	SEM Morphology/Description	Comments
25	DCM	1.0	0:100	18.0	0.1	100	35	-	0.2	-	-	-	Poloxamer did not precipitate under these conditions.
26	DCM	2.5	70:30 (70.9)	18.0	0.1	100	35	200	0.2	36	14.8	Non-uniform plates and angular particles up to 30 μm in size	Severe nozzle blockages. Low yield.
27	DCM	1.75	100:0	18.0	0.1	100	35	35	0.75	62	6.4	Non-uniform plates and angular particles up to 10 μm in size	Large nozzle tip to reduce nozzle blocking. Concentration reduced.
28	DCM	1.75	100:0	18.0	0.2	100	35	80	0.75	58	6.1	Non-uniform plates and angular particles up to 10 μm in size	Increase solution flow to reduce nozzle blockages.
29	DCM	1.75	100:0	18.0	0.2	100	35	50	-	67	11.3	Large non-uniform chunks up to 20 μm in size	No nozzle tip.
30	DCM	2.0	100:0	18.0	0.2	90	70	100	0.2	82	5.2	Clusters of small rounded particles < 2 μm	Temperature too high to process poloxamer.
31	DCM	1.0	100:0	18.0	0.1	75	35	65	0.2	75	2.4	Clusters of small rounded particles < 2 μm	Reduced T + P, solution conc. and flow rate to get smaller particles
32	DCM	1.0	70:30 (70.1)	18.0	0.1	75	35	45	0.2	82	19.0	Clusters of small plates < 6 μm	Introduction of poloxamer changes morphology and particle size.
33	DCM	1.0	50:50 (46.6)	18.0	0.1	75	35	45	0.2	59	-	Agglomerated large plates	Very agglomerated sample.
34	DCM	1.0	20:80	18.0	0.1	75	35	40	0.2	4	-	Agglomerated poloxamer plates	Particles are difficult to precipitate at higher poloxamer contents.
35	DCM	1.0	70:30 (74.7)	18.0	0.2	75	35	40	0.2	27	-	Clusters of plates up to 20 μm	Solution flow increased to get higher throughput. Yield reduced.
36	DCM	1.0	85:15 (85.0)	18.0	0.1	75	35	150	0.2	85	11.3	Clusters of small plates < 8 μm	Particles appear clustered rather than agglomerated together.
37	DCM	3.0	100:0	18.0	0.2	90	68	350	0.2	75	4.5	-	Run abandoned midway due to extreme nozzle blockages.
38	DCM	2.0	100:0	18.0	0.15	75	35	150	0.2	92	2.0	Well defined rounded particles < 2 μm. No agglomeration	Repeat of run 31 but throughput increased.
39	DCM	2.0	100:0 (95.8)	18.0	0.15	75	35	250	0.2	87	2.1	Well defined rounded particles < 2 μm. No agglomeration	Repeat of run 38 to produce a larger batch.
40	DCM	2.0	70:30 (71.3)	18.0	0.15	75	35	250	0.2	95	20.9	Agglomerated plates up to 10 μm in size	Wide size distribution. Particle size increase with more poloxamer.
41	DCM	2.0	70:30 (70.7)	18.0	0.15	75	35	170	0.2	95	21.7	Agglomerated plates up to 10 μm in size	Material added to run 40 material.
42	DCM	2.0	50:50 (53.7)	18.0	0.15	75	35	100	0.2	77	32.4	Agglomerated plates up to 20 μm in size	Larger particles with increase in poloxamer.
43	DCM	2.0	85:15 (86.2)	18.0	0.15	75	35	170	0.2	96	12.3	Agglomerated plates up to 10 μm in size	Particle size reduced with lower poloxamer content.

Table 16 - Compound (II) and HPC

Run No.	Solvent	Soln. Conc. (w/v)	Drug:Polymer (Polym. Type)	CO ₂ Flow (ml/min)	Soln. Flow (ml/min)	Pressure (bar)	Temp (°C)	ΔP (bar)	Nozzle Size (mm)	Yield (%)	Particle Size VMD (μm)	SEM Description/Morphology	Comments
1	35:65 v/v DCM/EtOH	1.0	100:0	20	0.1	90	70	200	0.2	74	4.0	Small discrete rounded/granular particles	Fine powder, phase-split conditions (similar to Compound (I))
2	35:65 v/v DCM/MeOH	1.0	100:0	20	0.1	90	70	110	0.2	66	5.5	Slightly aggregated plate-like rounded particles	MeOH does not appear to help
3	35:65 v/v DCM/EtOH	1.0	100:0	20	0.2	120	60	140	0.2	78	4.5	Slightly larger rounded/granular particles	More angular particles produced with homogeneous conditions
4	35:65 v/v DCM/EtOH	1.0	100:0	20	0.2	150	50	200	0.2	64	6.6	Small irregular chunks	Chunk like particles with higher density CO ₂
5	35:65 v/v DCM/EtOH	1.0	100:0	20	0.1	150	50	250	0.2	59	8.5	Irregular chunks up to 25μm	Problem with BPR during run may have caused larger particles
6	35:65 v/v DCM/EtOH	1.0	85:15 (HPC)	20	0.1	120	60	60	0.2	81	10.3	Dual morphology. Small < 3μm and larger acicular particles	Reduced ΔP. Polymer and drug appear to crystallise separately
7	35:65 v/v DCM/EtOH	1.0	85:15 (HPC)	20	0.1	90	70	150	0.2	81	4.6	Clusters of rounded/granular particles	Some fused particles. Sample appears to be a co-precipitate
8	35:65 v/v DCM/EtOH	1.0	85:15 (Low Mw HPC)	20	0.1	90	70	150	0.2	82	4.6	Clusters of rounded/granular particles	Sample appears to be a co-precipitate
9	35:65 v/v DCM/EtOH	1.0	85:15 (Low Mw HPC)	20	0.1	120	60	70	0.2	85	11.0	Dual morphology. Small < 3μm and larger acicular particles	Reduced ΔP. Polymer and drug appear to crystallise separately
10	Acetone	1.75	15:85 (HPC)	20	0.1	120	60	5	0.2	-	-	-	(30 ml vessel). Stringy polymer mass on nozzle tip
11	Acetone	1.75	15:85 (HPC)	20	0.1	120	60	30	0.1	46	-	Small primary particles < 4 μm heavily aggregated/fused. True co-precipitate	(300 ml vessel). Coarse white powder covering entire vessel
12	61:39 v/v Acetone/Cyclohexane	1.2	15:85 (HPC)	20	0.1	120	60	20	0.1	34	-	Small primary particles < 5 μm heavily aggregated/fused. True co-precipitate	(500 ml vessel). Coarse white powder covering entire vessel. Poor yield
13	Acetone	2.0	20:80 (HPC)	20	0.1	90	70	10	0.1	61	36.5	Small primary particles < 5 μm heavily aggregated/fused. True co-precipitate	(500 ml vessel). Coarse white powder covering entire vessel

Table 17 - Compound (ID) and HPC (contd)

Run No.	Solvent	Soln. Conc. (w/v)	Drug: Polymer (Polym. Type)	CO ₂ Flow (ml/min)	Soln. Flow (ml/min)	Pressure (bar)	Temp (°C)	ΔP (bar)	Nozzle Size (mm)	Yield (%)	Particle Size VMD (μm)	SEM Description/Morphology	Comments
14	Acetone	2.1	30:70 (Low Mw HPC)	200	0.1	150	50	>200?	0.1	37	-	Small primary particles < 5 μm heavily aggregated/fused. True co-precipitate	(500 ml vessel). Coarse white powder covering entire vessel. Problem with run (ΔP)
15	Acetone	2.1	30:70 (Low Mw HPC)	200	0.1	120	60	20	0.2	80	-	-	(50 ml vessel). Stringy polymer mass on nozzle tip
16	Acetone	2.0	25:75 (HPC)	200	1.0	120	60	5	0.2	60	37.9	Small primary particles < 5 μm heavily aggregated/fused. True co-precipitate	Pilot Plant. Coarse/fibrous powder covering vessel walls
17	Acetone	2.0	25:75 (HPC)	200	1.0	120	60	5	0.2	62	12.0	Small primary particles < 5 μm heavily aggregated/fused. True co-precipitate	Pilot Plant. Coarse/fibrous powder covering vessel walls
18	Acetone	2.0	30:70 (HPC)	200	1.0	120	60	15	0.2	62	47.1	Dual morphology. Small particles < 4 μm and thin wafer like plates.	Pilot Plant. Coarse/fibrous powder covering vessel walls
19	35:65 v/v DCM/EtOH	1.0	90:10 (HPC)	200	1.0	90	50	60	0.2	71	7.9	Dual morphology. Small particles < 2 μm but mostly thin wafer like plates.	Pilot Plant. Light, fluffy powder covering whole vessel
20	Acetone	2.0	50:50 (HPC)	200	1.0	120	60	20	0.2	66	33.7	Small primary particles < 3 μm heavily aggregated/fused. Appear to be co-precipitate	Pilot Plant. Coarse/fibrous powder covering vessel walls
21	20:55 v/v Acetone/Cyclohexane	1.3	20:80 (P237)	200	1.0	75	35	5	0.2	<10	-	-	Pilot Plant. Thin white film coating walls.
22	Acetone	2.0	50:50 (P237)	200	1.0	80	35	30	0.2	20	-	Agglomerated/fused irregular shaped chunks	Pilot Plant. Thin white powder film coating walls.
23	Acetone	2.0	70:30 (HPC)	200	1.0	120	60	60	0.2	50	13.4	Small primary particles < 3 μm heavily aggregated/fused.	Pilot Plant. Light, fluffy powder covering whole vessel
24	35:65 v/v DCM/EtOH	1.0	90:10 (HPC)	200	1.0	90	52	45	0.2	65	6.7	Dual morphology. Small particles < 2 μm but mostly thin wafer like plates.	Pilot Plant. Light, fluffy powder covering whole vessel
25	Acetone	2.0	10:90 (HPC)	200	1.0	120	60	5	0.2	63	>100	Small primary particles < 3 μm very heavily aggregated/fused.	Pilot Plant. Coarse/fibrous powder covering vessel walls

References

- 1 Ford, J.L., (1986) The Current Status of Solid Dispersions. *Pharm. Acta Helv* 61(3), 69-88.
- 5 2 Yoshioka M., Hancock, B.C. and Zografi, G., (1995) Inhibition of Indomethacin Crystallisation in Poly(vinylpyrrolidone) Coprecipitates. *J. Pharm. Sci.* 84(8), 983-986.
- 3 Yoshioka, M., Hancock, B. C., Zografi, G. (1995) Crystallization of
10 Indomethacin from the Amorphous State below and above its Glass Transition Temperature :- *J. Pharm. Sci.* 83, 1700-1705.
- 4 Byrn, S. R., Pfeiffer, R. R. and Stowell, J. G. (1999) Solid-State Chemistry of Drugs, Second Edition SSCI Inc., West Lafayette, Indiana, USA, 249-258.
- 15 5 Serajuddin, A. T. M. (1999) Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises, Subsequent Problems and Recent Breakthroughs. *J. Pharm. Sci.* 88(10), 1058-1066.
- 20 6 Matsumoto, T. and Zografi, G. (1999) Physical Properties of Solid Molecular Dispersions of Indomethacin with Poly(vinylpyrrolidone) and Poly(vinylpyrrolidone-co-vinylacetate) in Relation to Indomethacin Crystallisation, *Pharm. Res.* 16(11) 1722-1728.
- 7 Brocchini, S., Synthetic Polymers for Drug Delivery Applications, *World*
25 *Markets Series "Business Briefing", Pharma Tech, Drug Delivery Supplement*, May 2000, 216-221.
- 8 Sakellariou, P., and Rowe, R.C., (1995) Interactions in Cellulose Derivative Films for Oral Drug Delivery. *Pro. Polym. Sci.*, 20, 889-942.
- 30 9 Hancock, B.C., York, P. and Rowe, R.C. (1997) The Use of Solubility Parameters in Pharmaceutical Dosage Form Design. *Int. J. Pharm.* 148, 1-21.


- 10 Romero S., Reillo A., Escalera B. and Bustamente P., The Behaviour of
Paracetamol in Mixtures of Amphiprotic and Amphiprotic-Aprotic Solvents.
Relationship of Solubility Curves to Specific and Nonspecific Interactions 1996, *Chem.*
5 *Pharm. Bull.* 44(5), 1061-1064.
- 11 Subrahmanyam C. V. S., Sreenivasa Reddy M., Venkata Rao J. and Gundu Rao
P., Irregular Solution Behaviour of Paracetamol in Binary Solvents, 1992, *Int. J. Phar.*
78 (1992) 17-24.
- 10
- 12 Barra J., Lescure F., Doelker E. and Bustamente P., The Expanded Hansen
Approach to Solubility Parameters. Paracetamol and Citric Acid in Individual Solvents,
1997, *J. Pharm. Pharmacol.* 49 644-651.
- 15

Claims

- 1 A coformulation of an active substance and an oligomeric or polymeric material,
in which between 80 and 100% of the active substance is present in an amorphous as
5 opposed to crystalline form, wherein the amorphous phase active substance is stable, with
respect to its crystalline form(s) for at least three months after its preparation when stored
at between 0 and 10°C, provided that when the active substance is indomethacin, the
polymer is not poly vinyl pyrrolidone.
- 10 2 A coformulation of an active substance and an oligomeric or polymeric material,
in which between 80 and 100% of the active substance is present in an amorphous as
opposed to crystalline form, wherein the amorphous phase active substance is stable, with
respect to its crystalline form(s) for at least six months after its preparation when stored
at between 0 and 10°C.
- 15 3 A coformulation according to claim 1 or claim 2, wherein the amorphous phase
active substance is stable for at least twenty four months after its preparation, when
stored at between 0 and 10°C.
- 20 4 A coformulation according to claim 1, claim 2 or claim 3, wherein the
amorphous phase active substance is stable for the specified storage period, when stored
at 25°C.
- 5 A coformulation according to any one of the preceding claims, wherein the
25 active substance comprises a pharmaceutically active substance.
- 6 A coformulation according to claim 5, wherein the active substance is selected
from the group consisting of paracetamol, ketoprofen, indomethacin, carbamazepine,
theophylline and ascorbic acid.
- 30 7 A coformulation according to claim 5, wherein the active substance is a COX-2
selective inhibitor.

8 A coformulation according to claim 7, wherein the COX-2 selective inhibitor is a diarylheterocycle.

5 9 A coformulation according to claim 7, wherein the COX-2 selective inhibitor is selected from the group consisting of (Z)-3-[1-(4-bromophenyl)-1-(4-methylsulfonylphenyl)methylene] dihydrofuran-2-one, (Z)-3-[1-(4-chlorophenyl)-1-(4-methylsulfonylphenyl)methylene] dihydrofuran-2-one, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5*H*)-furanone and the compound of Formula (III):



10 A coformulation of (i) an active substance selected from the group consisting of
 15 paracetamol, ketoprofen, indomethacin, carbamazepine, theophylline and ascorbic acid
 and (ii) an oligomeric or polymeric material, in which between 80 and 100% of the active
 substance is present in an amorphous as opposed to crystalline form, and in which the
 active substance represents at least 10% of the coformulation, provided that when the
 active substance is indomethacin or theophylline, the oligomeric or polymeric material is
 20 not poly vinyl pyrrolidone.

11 A coformulation according to any one of the preceding claims, wherein the
 oligomeric or polymeric material is selected from the group consisting of cellulosic
 materials (including cellulose derivatives), vinyl polymers, poly lactic or glycolic acids
 25 (including lactide/glycolide copolymers), and mixtures thereof.

- 12 A coformulation according to any one of the preceding claims, wherein the active substance is a polar substance and the oligomeric or polymeric material is hydrophobic.
- 5 13 A coformulation according to any one of the preceding claims, wherein 100% of the active substance is present in an amorphous as opposed to crystalline form.
- 14 A coformulation according to any one of the preceding claims, wherein the active substance represents at least 20% of the coformulation.
- 10 15 A coformulation according to any one of the preceding claims, comprising an intimate single-phase mixture of the active substance and the oligomeric or polymeric material, from which the dissolution rate of the active substance in an aqueous medium is no higher for the first 30 minutes than it is subsequently.
- 15 16 A coformulation according to claim 15, wherein the dissolution rate of the active substance in an aqueous medium is no higher for the first 60 minutes than it is subsequently.
- 20 17 A coformulation of paracetamol and an oligomeric or polymeric material, in which between 80 and 100% of the paracetamol is present in an amorphous as opposed to crystalline form, and in which the paracetamol represents at least 1% of the coformulation.
- 25 18 A coformulation according to claim 17 wherein 100% of the paracetamol is present in an amorphous form.
- 19 A coformulation according to claim 17 or claim 18, wherein the paracetamol represents at least 25% of the coformulation.

30

- 20 A coformulation according to any one of claims 17 to 19, wherein the amorphous phase paracetamol is stable, with respect to its crystalline form(s) for at least three months after its preparation, when stored at between 0 and 10°C.
- 5 21 A coformulation according to any one of the preceding claims, which has been prepared by a SEDS™ process.
- 22 A coformulation of an active substance and an oligomeric or polymeric material, according to any one of claims 1, 2, 10 or 17, the coformulation being substantially as
10 herein described with reference to the accompanying illustrative drawings.
- 23 A pharmaceutical composition containing a coformulation according to any one of the preceding claims.
- 15 24 A method for preparing a coformulation according to any one of claims 1 to 22, which method involves the use of a SEDS™ process.
- 25 Use of a SEDS™ process to prepare a coformulation of an active substance and an oligomeric or polymeric material, in which between 80 and 100% of the active
20 substance is present in an amorphous as opposed to crystalline form, and in which the active substance represents at least 10% of the coformulation.
- 26 A method for preparing a coformulation of an active substance and an oligomeric or polymeric material, using an anti-solvent-induced particle formation
25 process, wherein, under the operating conditions used, the active substance is soluble in the chosen "anti-solvent" but the oligomeric or polymeric material is not.
- 27 A method according to claim 26, wherein the particle formation process is a SEDS™ process.
- 30 28 A method according to claim 26 or claim 27, wherein the anti-solvent is supercritical carbon dioxide.

29 A method according to any one of claims 26 to 28, wherein the active substance is ketoprofen.


30 A method according to any one of claims 26 to 29, wherein the oligomeric or
5 polymeric material is hydroxypropyl methyl cellulose.

31 A method for preparing a coformulation of an active substance and an oligomeric or polymeric material, the method being substantially as herein described with reference to the accompanying illustrative drawings.

10

1/21

Fig.1.




2/21

Fig.2.



Fig.3.




3/21

Fig.4.




Fig.5.




4/21

Fig.6.




5/21

Fig.7.



6/21

Fig.8.



7/21

Fig.9.





Fig.10.



8/21

Fig.11.





Fig.12.



9/21

Fig.13.






Fig.14.



10/21

Fig.15.



11/21

Fig.16.





Fig.17.



12/21

Fig.18.






Fig.19.




13/21

Fig.20.




14/21

Fig.21.





15/21

Fig.22.



16/21





18/21

Fig.25.





Fig.26.



19/21

Fig.27.





Fig.28.



20/21

Fig.29.






Fig.30.



21/21



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15664 A3

(51) International Patent Classification⁷: **A61K 9/16**

(21) International Application Number: **PCT/GB00/03328**

(22) International Filing Date: **31 August 2000 (31.08.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
9920558.5 31 August 1999 (31.08.1999) **GB**

(71) Applicants (*for all designated States except US*): **BRADFORD PARTICLE DESIGN PLC** [GB/GB]; Unit 69 Listerhills Science Park, Campus Road, Bradford BD7 1HR (GB). **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Princetown, NJ 08543-4000 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **YORK, Peter** [GB/GB]; 47 Parish Ghyll Drive, Ilkley LS29 9PR (GB). **WILKINS, Simon, Anthony** [GB/GB]; 8 Beckbury Street, Farsley, Leeds LS28 5BP (GB). **STOREY, Richard, Anthony** [GB/GB]; 18 Laurel Way, Chartham, Canterbury, Kent CT4 7TJ (GB). **WALKER, Stephen, Ernest** [GB/GB]; Roundwood Grange, Roundwood Road, Baildon, Shipley, West Yorkshire BD17 7JX (GB). **HARLAND, Ronald, Scott** [US/US]; 1 Harlow Court, Yardley, PA 19067 (US).

(74) Agents: **BREWSTER, Andrea, Ruth et al.**; Greaves Brewster, 24A Woodborough Road, Winscombe, North Somerset BS25 1AD (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

[Continued on next page]

(54) Title: **COFORMULATION METHODS AND THEIR PRODUCTS**



(57) Abstract: A coformulation of an active (preferably pharmaceutically active, for instance a COX-2 enzyme inhibitor) substance and an oligomeric or polymeric excipient, containing at least 10 % of the active, between 80 and 100 % of which is amorphous. The amorphous phase is stable, with respect to the crystalline phase(s), for at least three months after its preparation when stored at between 0 and 10 °C. The invention also provides processes, preferably involving SEDSTM particle formation, for preparing such a coformulation.



WO 01/15664 A3



LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

Published:

— *with international search report*

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) **Date of publication of the international search report:**
20 September 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/GB 00/03328

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 852 140 A (NISSAN CHEMICAL IND LTD) 8 July 1998 (1998-07-08) column 1, line 5 - line 12 page 11 -page 12; examples 1-7 ----	1-6, 10-16, 23,31
X	WO 96 31202 A (ELAN CORP PLC) 10 October 1996 (1996-10-10) page 3, line 13 - line 16 page 7 -page 8; example 1 ----	1-5,23, 31
X	EP 0 582 169 A (BAYER ITALIA SPA) 9 February 1994 (1994-02-09) page 3; example 1 ----	1-5,23, 31
X	WO 92 11000 A (SANOL ARZNEI SCHWARZ GMBH) 9 July 1992 (1992-07-09) page 6 -page 7; examples 1,2 ----	1-5,23, 31
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

22 February 2001

Date of mailing of the international search report

02/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/GB 00/03328

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 13136 A (MICROENCAPSULATION CENTRE ;RICHARD JOEL (FR); BENOIT JEAN PIERRE () 2 April 1998 (1998-04-02) page 1, line 4 - line 28 page 5, line 5 -page 7, line 18 page 12 -page 13; example 9 ---	1-5, 23, 31
X	WO 99 25322 A (CARLI FABIO ;COLOMBO ITALO (IT); ALESSI PAOLO (IT); CORTESI ANGELO) 27 May 1999 (1999-05-27) page 4 -page 5; examples 1,6 ---	1-5, 23, 31
X	WO 97 31691 A (UNIV KANSAS ;SUBRAMANIAM BALA (US); SAID SAID (US); RAJEWSKI ROGER) 4 September 1997 (1997-09-04) page 1, line 16 - line 26 page 15 -page 23; examples 1-4 ---	1-5, 23, 31
X	WO 95 01221 A (UNIV BRADFORD ;HANNA MAZEN (GB); YORK PETER (GB)) 12 January 1995 (1995-01-12) cited in the application page 37 -page 50; examples 5,10,16 ---	1-5, 23, 31
X	DEBENEDETTI P G ET AL: "APPLICATION OF SUPERCritical FLUIDS FOR THE PRODUCTION OF SUSTAINED DELIVERY DEVICES" JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 24, no. 1 / 03, 1 May 1993 (1993-05-01), pages 27-44, XP000303918 ISSN: 0168-3659 the whole document ---	1-5, 23, 31
P,X	WILKINS S. ET AL: "The formation of indomethacin:polymer co-precipitates by the solution enhanced dispersion by supercritical fluids (SEDS) process" J. OF PHARMACY AND PHARMACOLOGY, vol. 51, September 1999 (1999-09), page 291 XP000905174 the whole document ---	1-6, 10-31
X	TAYLOR L. ET AL: "Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions" PHARM. RES., vol. 14, 1997, pages 1691-1698, XP000905065 page 1691 -page 1692 page 1695 --- -/-	1-6, 10-23, 31

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/03328

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHEKUNOV B. ET AL: "Control of Particle Morphology using solution enhanced dispersion by supercritical fluids (SEDS)" PHARM. RES., vol. 14, 1997, pages 195-196, XP000905093 the whole document ---	1
E	WO 01 03821 A (YORK PETER ;BRADFORD PARTICLE DESIGN PLC (GB); HANNA MAZEN HERMIZ) 18 January 2001 (2001-01-18) page 8, line 14 - line 21 page 22 -page 23; example 3 ---	1-6, 10-23,31
X	US 4 404 183 A (KAWATA HIROITSU ET AL) 13 September 1983 (1983-09-13) claims 1,2 ---	1-6, 10-16, 23,31
A	WO 97 44028 A (MERCK FROSST CANADA INC ;HANCOCK BRUNO (CA); WINTERS CONRAD (CA);) 27 November 1997 (1997-11-27) the whole document -----	7,8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/03328

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0852140 A	08-07-1998	AU 702088 B	11-02-1999
		AU 6669396 A	12-03-1997
		NO 980549 A	02-04-1998
		NZ 315089 A	29-06-1999
		CA 2228907 A	27-02-1997
		CN 1192677 A	09-09-1998
		CZ 9800326 A	17-06-1998
WO 9631202 A	10-10-1996	WO 9706781 A	27-02-1997
		IE 950233 A	16-10-1996
		AU 700612 B	07-01-1999
		AU 5286696 A	23-10-1996
		CA 2217462 A	10-10-1996
		EP 0818996 A	21-01-1998
		JP 11503147 T	23-03-1999
EP 0582169 A	09-02-1994	NZ 304975 A	24-09-1998
		US 5641745 A	24-06-1997
		ZA 9602670 A	09-10-1996
		IT 1255792 B	16-11-1995
		CA 2101680 A	06-02-1994
		JP 7002700 A	06-01-1995
		US 5491154 A	13-02-1996
WO 9211000 A	09-07-1992	US 5622978 A	22-04-1997
		DE 4041563 A	25-06-1992
		AT 116542 T	15-01-1995
		CA 2098814 A	23-06-1992
		DE 59104172 D	16-02-1995
		DK 563176 T	06-03-1995
		EP 0563176 A	06-10-1993
WO 9813136 A	02-04-1998	ES 2067324 T	16-03-1995
		FI 932761 A	16-06-1993
		GR 3015623 T	30-06-1995
		HU 217817 B	28-04-2000
		IE 914313 A	01-07-1992
		JP 6504531 T	26-05-1994
		KR 162105 B	01-12-1998
WO 9925322 A	27-05-1999	PT 99892 A, B	31-12-1992
		US 5424076 A	13-06-1995
		FR 2753639 A	27-03-1998
		AT 194926 T	15-08-2000
		DE 69702666 D	31-08-2000
		EP 0930936 A	28-07-1999
		ES 2149613 T	01-11-2000
WO 9731691 A	04-09-1997	PT 930936 T	29-12-2000
		IT 1296464 B	25-06-1999
		AU 2153199 A	07-06-1999
		BR 9814656 A	03-10-2000
		EP 1033977 A	13-09-2000
		US 5874029 A	23-02-1999
		US 5833891 A	10-11-1998
		AU 709384 B	26-08-1999
		AU 2193697 A	16-09-1997
		CA 2247900 A	04-09-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/03328

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9731691 A		EP 0885038 A	23-12-1998
WO 9501221 A	12-01-1995	AT 174530 T	15-01-1999
		AU 677345 B	17-04-1997
		AU 7007194 A	24-01-1995
		CA 2166301 A	12-01-1995
		DE 69415320 D	28-01-1999
		DE 69415320 T	24-06-1999
		DK 706421 T	23-08-1999
		EP 0706421 A	17-04-1996
		ES 2128564 T	16-05-1999
		GR 3029612 T	30-06-1999
		JP 8511987 T	17-12-1996
		NZ 267697 A	26-05-1997
		SG 47392 A	17-04-1998
		US 5851453 A	22-12-1998
WO 0103821 A	18-01-2001	NONE	
US 4404183 A	13-09-1983	JP 1272484 C	11-07-1985
		JP 56133217 A	19-10-1981
		JP 59048810 B	29-11-1984
		JP 1591530 C	30-11-1990
		JP 2009007 B	28-02-1990
		JP 56049314 A	02-05-1981
		CA 1146866 A	24-05-1983
		CH 648484 A	29-03-1985
		DE 3024858 A	22-01-1981
		ES 493152 D	16-11-1981
		ES 8200557 A	01-02-1982
		ES 499854 D	01-06-1982
		ES 8205125 A	16-09-1982
		FR 2460667 A	30-01-1981
		FR 2489146 A	05-03-1982
		GB 2053681 A, B	11-02-1981
		IT 1132169 B	25-06-1986
		SE 448342 B	16-02-1987
		SE 8004938 A	06-01-1981
		US 4343789 A	10-08-1982
		US 4673564 A	16-06-1987
WO 9744028 A	27-11-1997	AU 3004997 A	09-12-1997
		BG 103000 A	30-09-1999
		BR 9709097 A	03-08-1999
		CZ 9803738 A	16-06-1999
		EP 0910368 A	28-04-1999
		HR 970262 A	30-06-1998
		JP 11512754 T	02-11-1999
		NO 985342 A	16-11-1998
		PL 329940 A	26-04-1999
		SK 156798 A	18-01-2000
		TR 9802345 T	22-03-1999
		US 6063811 A	16-05-2000

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15664 A3

(51) International Patent Classification⁷: **A61K 9/16**

(21) International Application Number: **PCT/GB00/03328**

(22) International Filing Date: **31 August 2000 (31.08.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
9920558.5 31 August 1999 (31.08.1999) **GB**

(71) Applicants (*for all designated States except US*): **BRADFORD PARTICLE DESIGN PLC** [GB/GB]; Unit 69 Listerhills Science Park, Campus Road, Bradford BD7 1HR (GB). **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Princetown, NJ 08543-4000 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **YORK, Peter** [GB/GB]; 47 Parish Ghyll Drive, Ilkley LS29 9PR (GB). **WILKINS, Simon, Anthony** [GB/GB]; 8 Beckbury Street, Farsley, Leeds LS28 5BP (GB). **STOREY, Richard, Anthony** [GB/GB]; 18 Laurel Way, Chartham, Canterbury, Kent CT4 7TJ (GB). **WALKER, Stephen, Ernest** [GB/GB]; Roundwood Grange, Roundwood Road, Baildon, Shipley, West Yorkshire BD17 7JX (GB). **HARLAND, Ronald, Scott** [US/US]; 1 Harlow Court, Yardley, PA 19067 (US).

(74) Agents: **BREWSTER, Andrea, Ruth et al.**; Greaves Brewster, 24A Woodborough Road, Winscombe, North Somerset BS25 1AD (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

[Continued on next page]

(54) Title: **COFORMULATION METHODS AND THEIR PRODUCTS**



(57) Abstract: A coformulation of an active (preferably pharmaceutically active, for instance a COX-2 enzyme inhibitor) substance and an oligomeric or polymeric excipient, containing at least 10 % of the active, between 80 and 100 % of which is amorphous. The amorphous phase is stable, with respect to the crystalline phase(s), for at least three months after its preparation when stored at between 0 and 10 °C. The invention also provides processes, preferably involving SEDSTM particle formation, for preparing such a coformulation.

WO 01/15664 A3



LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

Published:

— with international search report

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:

20 September 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/03328

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 852 140 A (NISSAN CHEMICAL IND LTD) 8 July 1998 (1998-07-08) column 1, line 5 - line 12 page 11 -page 12; examples 1-7 ---	1-6, 10-16, 23,31
X	WO 96 31202 A (ELAN CORP PLC) 10 October 1996 (1996-10-10) page 3, line 13 - line 16 page 7 -page 8; example 1 ---	1-5,23, 31
X	EP 0 582 169 A (BAYER ITALIA SPA) 9 February 1994 (1994-02-09) page 3; example 1 ---	1-5,23, 31
X	WO 92 11000 A (SANOL ARZNEI SCHWARZ GMBH) 9 July 1992 (1992-07-09) page 6 -page 7; examples 1,2 ---	1-5,23, 31
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 February 2001

Date of mailing of the international search report

02/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

INTERNATIONAL SEARCH REPORT

Int .ional Application No
PCT/GB 00/03328

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 13136 A (MICROENCAPSULATION CENTRE ;RICHARD JOEL (FR); BENOIT JEAN PIERRE () 2 Apr11 1998 (1998-04-02) page 1, line 4 - line 28 page 5, line 5 -page 7, line 18 page 12 -page 13; example 9 ---	1-5,23, 31
X	WO 99 25322 A (CARLI FABIO ;COLOMBO ITALO (IT); ALESSI PAOLO (IT); CORTESI ANGELO) 27 May 1999 (1999-05-27) page 4 -page 5; examples 1,6 ---	1-5,23, 31
X	WO 97 31691 A (UNIV KANSAS ;SUBRAMANIAM BALA (US); SAID SAID (US); RAJEWSKI ROGER) 4 September 1997 (1997-09-04) page 1, line 16 - line 26 page 15 -page 23; examples 1-4 ---	1-5,23, 31
X	WO 95 01221 A (UNIV BRADFORD ;HANNA MAZEN (GB); YORK PETER (GB)) 12 January 1995 (1995-01-12) cited in the application page 37 -page 50; examples 5,10,16 ---	1-5,23, 31
X	DEBENEDETTI P G ET AL: "APPLICATION OF SUPERCRITICAL FLUIDS FOR THE PRODUCTION OF SUSTAINED DELIVERY DEVICES" JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 24, no. 1 / 03, 1 May 1993 (1993-05-01), pages 27-44, XP000303918 ISSN: 0168-3659 the whole document ---	1-5,23, 31
P,X	WILKINS S. ET AL: "The formation of indomethacin:polymer co-precipitates by the solution enhanced dispersion by supercritical fluids (SEDS) process" J. OF PHARMACY AND PHARMACOLOGY, vol. 51, September 1999 (1999-09), page 291 XP000905174 the whole document ---	1-6, 10-31
X	TAYLOR L. ET AL: "Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions" PHARM. RES., vol. 14, 1997, pages 1691-1698, XP000905065 page 1691 -page 1692 page 1695 ---	1-6, 10-23,31

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/03328

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHEKUNOV B. ET AL: "Control of Particle Morphology using solution enhanced dispersion by supercritical fluids (SEDS)" PHARM. RES., vol. 14, 1997, pages 195-196, XP000905093 the whole document	1
E	WO 01 03821 A (YORK PETER ;BRADFORD PARTICLE DESIGN PLC (GB); HANNA MAZEN HERMIZ) 18 January 2001 (2001-01-18) page 8, line 14 - line 21 page 22 -page 23; example 3	1-6, 10-23,31
X	US 4 404 183 A (KAWATA HIROITSU ET AL) 13 September 1983 (1983-09-13) claims 1,2	1-6, 10-16, 23,31
A	WO 97 44028 A (MERCK FROSST CANADA INC ;HANCOCK BRUNO (CA); WINTERS CONRAD (CA);) 27 November 1997 (1997-11-27) the whole document	7,8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/03328

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0852140 A	08-07-1998	AU 702088 B	11-02-1999
		AU 6669396 A	12-03-1997
		NO 980549 A	02-04-1998
		NZ 315089 A	29-06-1999
		CA 2228907 A	27-02-1997
		CN 1192677 A	09-09-1998
		CZ 9800326 A	17-06-1998
		WO 9706781 A	27-02-1997
WO 9631202 A	10-10-1996	IE 950233 A	16-10-1996
		AU 700612 B	07-01-1999
		AU 5286696 A	23-10-1996
		CA 2217462 A	10-10-1996
		EP 0818996 A	21-01-1998
		JP 11503147 T	23-03-1999
		NZ 304975 A	24-09-1998
		US 5641745 A	24-06-1997
		ZA 9602670 A	09-10-1996
EP 0582169 A	09-02-1994	IT 1255792 B	16-11-1995
		CA 2101680 A	06-02-1994
		JP 7002700 A	06-01-1995
		US 5491154 A	13-02-1996
		US 5622978 A	22-04-1997
WO 9211000 A	09-07-1992	DE 4041563 A	25-06-1992
		AT 116542 T	15-01-1995
		CA 2098814 A	23-06-1992
		DE 59104172 D	16-02-1995
		DK 563176 T	06-03-1995
		EP 0563176 A	06-10-1993
		ES 2067324 T	16-03-1995
		FI 932761 A	16-06-1993
		GR 3015623 T	30-06-1995
		HU 217817 B	28-04-2000
		IE 914313 A	01-07-1992
		JP 6504531 T	26-05-1994
		KR 162105 B	01-12-1998
		PT 99892 A, B	31-12-1992
		US 5424076 A	13-06-1995
WO 9813136 A	02-04-1998	FR 2753639 A	27-03-1998
		AT 194926 T	15-08-2000
		DE 69702666 D	31-08-2000
		EP 0930936 A	28-07-1999
		ES 2149613 T	01-11-2000
		PT 930936 T	29-12-2000
WO 9925322 A	27-05-1999	IT 1296464 B	25-06-1999
		AU 2153199 A	07-06-1999
		BR 9814656 A	03-10-2000
		EP 1033977 A	13-09-2000
WO 9731691 A	04-09-1997	US 5874029 A	23-02-1999
		US 5833891 A	10-11-1998
		AU 709384 B	26-08-1999
		AU 2193697 A	16-09-1997
		CA 2247900 A	04-09-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/03328

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9731691	A		EP 0885038 A	23-12-1998
WO 9501221	A	12-01-1995	AT 174530 T	15-01-1999
			AU 677345 B	17-04-1997
			AU 7007194 A	24-01-1995
			CA 2166301 A	12-01-1995
			DE 69415320 D	28-01-1999
			DE 69415320 T	24-06-1999
			DK 706421 T	23-08-1999
			EP 0706421 A	17-04-1996
			ES 2128564 T	16-05-1999
			GR 3029612 T	30-06-1999
			JP 8511987 T	17-12-1996
			NZ 267697 A	26-05-1997
			SG 47392 A	17-04-1998
			US 5851453 A	22-12-1998
WO 0103821	A	18-01-2001	NONE	
US 4404183	A	13-09-1983	JP 1272484 C	11-07-1985
			JP 56133217 A	19-10-1981
			JP 59048810 B	29-11-1984
			JP 1591530 C	30-11-1990
			JP 2009007 B	28-02-1990
			JP 56049314 A	02-05-1981
			CA 1146866 A	24-05-1983
			CH 648484 A	29-03-1985
			DE 3024858 A	22-01-1981
			ES 493152 D	16-11-1981
			ES 8200557 A	01-02-1982
			ES 499854 D	01-06-1982
			ES 8205125 A	16-09-1982
			FR 2460667 A	30-01-1981
			FR 2489146 A	05-03-1982
			GB 2053681 A, B	11-02-1981
			IT 1132169 B	25-06-1986
			SE 448342 B	16-02-1987
			SE 8004938 A	06-01-1981
			US 4343789 A	10-08-1982
			US 4673564 A	16-06-1987
WO 9744028	A	27-11-1997	AU 3004997 A	09-12-1997
			BG 103000 A	30-09-1999
			BR 9709097 A	03-08-1999
			CZ 9803738 A	16-06-1999
			EP 0910368 A	28-04-1999
			HR 970262 A	30-06-1998
			JP 11512754 T	02-11-1999
			NO 985342 A	16-11-1998
			PL 329940 A	26-04-1999
			SK 156798 A	18-01-2000
			TR 9802345 T	22-03-1999
			US 6063811 A	16-05-2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.